2. 诱导疾病模型产品 Cell Cycle/DNA Damage Antibody-drug Conjugate/ADC Related Epigenetics PI3K/Akt/mTOR Autophagy Apoptosis Anti-infection Others
  3. 免疫与炎症疾病模型 心血管系统疾病模型 泌尿系统疾病模型 Topoisomerase ADC Payload AMPK Autophagy Apoptosis HIV HBV Mitophagy Antibiotic Bacterial Fluorescent Dye
  4. 肾炎模型 心脏疾病模型
  5. Doxorubicin hydrochloride

Doxorubicin hydrochloride  (Synonyms: 盐酸阿霉素; Hydroxydaunorubicin hydrochloride; ADR)

目录号: HY-15142 纯度: 99.90%
COA 产品使用指南 技术支持

Doxorubicin hydrochloride (Hydroxydaunorubicin hydrochloride; ADR) 是一种具有细胞毒性的蒽环类抗生素，是一种抗癌化疗试剂。Doxorubicin hydrochloride 是一种有效的人类 DNA topoisomerase I 和 topoisomerase II 抑制剂，IC50 分别为 0.8 μM 和 2.67 μM。Doxorubicin hydrochloride 可降低 AMPK 及其下游靶蛋白乙酰辅酶 A 羧化酶的磷酸化。还可诱导凋亡 (apoptosis) 和自噬。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CAS No. : 25316-40-9

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥990
In-stock
50 mg ￥900
In-stock
100 mg ￥1600
In-stock
200 mg ￥3000
In-stock
500 mg ￥5000
In-stock
1 g 现货 询价
2 g 现货 询价
5 g 现货 询价
10 g   询价  
50 g   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Doxorubicin hydrochloride:

Doxorubicin hydrochloride 相关抗体

Top Publications Citing Use of Products

MCE 顾客使用本产品发表的 581 篇科研文献

WB
IF
IHC
Cell Viability Assay

    Doxorubicin hydrochloride purchased from MCE. Usage Cited in: Mol Cancer. 2024 May 9;23(1):83.  [Abstract]

    Exhausted T-cells (NExT) loaded with Doxorubicin (5–50 nM; 48 h) significantly reduces the viability of SUM159 cells.

    Doxorubicin hydrochloride purchased from MCE. Usage Cited in: Bioact Mater. 2024 May 11:38:384-398.  [Abstract]

    Doxorubicin hydrochloride (10 μM; 3-5 days) significantly reduces the viability of lung cancer organoid-2 (LCO-2) and LCO-3, while showing no significant effect on LCO-1 viability.

    Doxorubicin hydrochloride purchased from MCE. Usage Cited in: Adv Funct Mater. 23 October 2021.

    Cell viability after incubated with free DOX under normoxia and hypoxia at various DOX (Doxorubicin) (0.65-20 μg/mL) concentrations for 24 h determined by MTT assay.

    Doxorubicin hydrochloride purchased from MCE. Usage Cited in: Nat Cell Biol. 2020 Sep;22(9):1056-1063.  [Abstract]

    UFMylation of endogenous p53 was analysed by western blot in HCT116 p53+/+ cells depleted of UFL1 or DDRGK1 upon DNA damage induced by doxorubicin (doxo; 1 µM; 24 h) or etoposide (eto; 25 µg ml−1; 12 h).

    Doxorubicin hydrochloride purchased from MCE. Usage Cited in: Cell Death Dis. 2019 Nov 25;10(12):887.  [Abstract]

    Doxorubicin or CPT-11 significantly promoted KRT8 expression in chordoma cells in vitro. Representative images of immunofluorescence staining of KRT8 of CM318 and UCH1 cell line.

    Doxorubicin hydrochloride purchased from MCE. Usage Cited in: Cell Death Dis. 2019 Nov 25;10(12):887.  [Abstract]

    Doxorubicin or CPT-11 significantly promoted KRT8 expression in chordoma cells in vitro. Western blotting analysis and quantification of KRT8 protein expression (normalized to GAPDH expression).

    Doxorubicin hydrochloride purchased from MCE. Usage Cited in: Free Radic Biol Med. 2019 Jan:130:557-567.  [Abstract]

    Representative pictures of Live/Dead staining of effects of 7,8-DHF on high dose of Dox-induced cell death and MMP reduction of H9c2 cells.

    Doxorubicin hydrochloride purchased from MCE. Usage Cited in: J Cell Mol Med. 2019 Sep;23(9):6034-6047.  [Abstract]

    Effects of YWPC (50 mg/L for 24 h) on DOX (5 μM for 24 h)-induces dissipation of mitochondrial membrane potential measured in H9C2 cells loaded with JC-1 using fluorescence microscopy.

    Doxorubicin hydrochloride purchased from MCE. Usage Cited in: Nat Commun. 2018 Oct 8;9(1):4139.  [Abstract]

    One hour after treated with UV or 2 h after treated with MMS, Camptothecin (CPT) (10 μM), or Doxorubicin (DOX; 0.5 μM), HEK293T cells expressing HA-SUMO2 and His-RhoB are subjected to sumoylation assay to detect the SUMO2 conjugation of RhoB.

    Doxorubicin hydrochloride purchased from MCE. Usage Cited in: J Clin Invest. 2018 Jan 2;128(1):483-499.  [Abstract]

    Immunoblotting for EZH2 in lysates of immortalized mouse podocytes after treatment with Adriamycin (300 ng/mL) for 48 hours (n=6).

    Doxorubicin hydrochloride purchased from MCE. Usage Cited in: J Exp Clin Cancer Res. 2018 Sep 19;37(1):232.  [Abstract]

    Immunoblotting shows that both P-gp protein expression is significantly decreased in 24 h after US exposure in MCF-7/ADR and HEPG2/ADM cells.

    Doxorubicin hydrochloride purchased from MCE. Usage Cited in: Nanoscale Res Lett. 2018 Nov 3;13(1):350.  [Abstract]

    HY-15142

    Doxorubicin hydrochloride purchased from MCE. Usage Cited in: Cell Signal. 2017 Aug:36:108-116.  [Abstract]

    PAQR3 affects DNA damage repair. AGS cells are treated with different doses of VP-16 (for 24 h), CDDP (for 24 h) and Doxorubicin (for 10 h) as indicated, followed by immunoblotting with the antibodies.

    Doxorubicin hydrochloride purchased from MCE. Usage Cited in: Cell Physiol Biochem. 2017;42(3):965-973.  [Abstract]

    U937 cells are treated with Thapsigargin (TG, 1 μM), NSC 125973 (PTX, 5nM) as well as Doxorubincin (DOX, 1 μM) for 12 hours and the indicated proteins are detected by Western blot.

    Doxorubicin hydrochloride purchased from MCE. Usage Cited in: Nat Med. 2016 May;22(5):547-56.  [Abstract]

    Immunofluorescent staining for α-actinin (ACTN2) and cardiac troponin T (TNNT2) to demonstrate sarcomeric organization in hiPSC–CMs derived from patients who do not experience Doxorubicin–induced cardiotoxicity (DOX) versus those who do experience Doxorubicin-induced cardiotoxicity (DOXTOX) after 24 h treatment with Doxorubicin. Scale bar, 20 µm.

    查看 Topoisomerase 亚型特异性产品:

    查看所有亚型
    Topoisomerase Topo I Topo II

    查看 ADC Payload 亚型特异性产品:

    查看所有亚型
    Auristatin Calicheamicins Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents

    查看 AMPK 亚型特异性产品:

    查看所有亚型
    NUAK1 NUAK2 AMPK AMPK α1β1γ1 AMPK α2β1γ1 AMPK α1β2γ1 AMPK α2β2γ1 BRSK1 BRSK2 HUNK AMPKα

    查看 HIV 亚型特异性产品:

    查看所有亚型
    HIV HIV-1 HIV-2

    查看 Antibiotic 亚型特异性产品:

    查看所有亚型
    Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

    • 生物活性

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    Doxorubicin hydrochloride (Hydroxydaunorubicin hydrochloride; ADR), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy[1][2][3].

    IC50 & Target[1][2][3]

    Topoisomerase I

    0.8 μM (IC50)

    Topoisomerase II

    2.67 μM (IC50)

    Daunorubicins/Doxorubicins

     

    HIV-1

     

    细胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    4T1 IC50
    0.8 μM
    Compound: ADR
    Antiproliferative activity against mouse 4T1 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against mouse 4T1 cells measured after 72 hrs by MTT assay
    		[PMID: 30739826]
    4T1 IC50
    2.4 μM
    Compound: Adriamycin
    Cytotoxicity against mouse 4T1 cells assessed as cell viability by MTT assay
    Cytotoxicity against mouse 4T1 cells assessed as cell viability by MTT assay
    		[PMID: 38387332]
    518A2 IC50
    0.12 μM
    Compound: 1
    Cytotoxicity against human 518A2 cells after 72 hrs by MTT assay
    Cytotoxicity against human 518A2 cells after 72 hrs by MTT assay
    		[PMID: 20133021]
    518A2 IC50
    0.17 μM
    Compound: 1
    Cytotoxicity against human 518A2 cells after 48 hrs by MTT assay
    Cytotoxicity against human 518A2 cells after 48 hrs by MTT assay
    		[PMID: 20133021]
    518A2 IC50
    0.34 μM
    Compound: 1
    Cytotoxicity against human 518A2 cells after 24 hrs by MTT assay
    Cytotoxicity against human 518A2 cells after 24 hrs by MTT assay
    		[PMID: 20133021]
    647-V IC50
    < 0.068 mg/mL
    Compound: Doxorubicin
    Cytotoxicity against human 647V cells after 24 hrs by MTT assay
    Cytotoxicity against human 647V cells after 24 hrs by MTT assay
    		[PMID: 22142614]
    769-P IC50
    11.5 μM
    Compound: Adriamycin
    Cytotoxicity against human 769-P cells by MTT assay
    Cytotoxicity against human 769-P cells by MTT assay
    		[PMID: 20627721]
    769-P IC50
    11.5 μM
    Compound: Adriamycin
    Cytotoxicity against human 769-P cells by MTT assay
    Cytotoxicity against human 769-P cells by MTT assay
    		[PMID: 21875764]
    786-0 GI50
    0.43 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human 786-0 cells assessed as growth inhibition by SRB assay
    Cytotoxicity against human 786-0 cells assessed as growth inhibition by SRB assay
    		[PMID: 24507920]
    786-0 IC50
    0.25 μM
    Compound: ADR
    Antiproliferative activity against human 786-0 cells incubated for 72 hrs by SRB method
    Antiproliferative activity against human 786-0 cells incubated for 72 hrs by SRB method
    		[PMID: 39054645]
    786-0 IC50
    3.1 μM
    Compound: Adriamycin
    Cytotoxicity against human 786-0 cells by MTT assay
    Cytotoxicity against human 786-0 cells by MTT assay
    		[PMID: 20627721]
    786-0 IC50
    3.1 μM
    Compound: Adriamycin
    Cytotoxicity against human 786-0 cells by MTT assay
    Cytotoxicity against human 786-0 cells by MTT assay
    		[PMID: 21875764]
    A 172 IC50
    18.5 μM
    Compound: Adriamycin
    Cytotoxicity against human A172 cells by MTT assay
    Cytotoxicity against human A172 cells by MTT assay
    		[PMID: 25304898]
    A-375 IC50
    0.73 μM
    Compound: Doxorubicin.HCl
    Cytotoxicity against human A375 cells after 48 hrs by MTT assay
    Cytotoxicity against human A375 cells after 48 hrs by MTT assay
    		[PMID: 23131338]
    A-375 IC50
    17.2 μM
    Compound: Adriamycin
    Cytotoxicity against human A375 cells by MTT assay
    Cytotoxicity against human A375 cells by MTT assay
    		[PMID: 20627721]
    A-375 IC50
    17.2 μM
    Compound: Adriamycin
    Cytotoxicity against human A375 cells by MTT assay
    Cytotoxicity against human A375 cells by MTT assay
    		[PMID: 21875764]
    A-427 IC50
    1.3 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human A-427 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human A-427 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 34176266]
    A-431 IC50
    0.009 μM
    Compound: Doxorubicin Hydrochloride
    Cytotoxicity against human A-431 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human A-431 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 37729693]
    A2780 GI50
    0.16 μM
    Compound: ADR
    Cytotoxicity against human A2780 cells after 48 hrs by SRB assay
    Cytotoxicity against human A2780 cells after 48 hrs by SRB assay
    		[PMID: 20444601]
    A2780 GI50
    0.16 μM
    Compound: ADR
    Cytotoxicity against human A2780 cells by sulforhodamine B method
    Cytotoxicity against human A2780 cells by sulforhodamine B method
    		[PMID: 21459581]
    A2780 GI50
    0.18 μM
    Compound: ADR
    Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21194809]
    A2780 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human A2780 cells after 48 hrs by SRB assay
    Cytotoxicity against human A2780 cells after 48 hrs by SRB assay
    		[PMID: 20554354]
    A2780 GI50
    < 0.1 μM
    Compound: ADR
    Anticancer activity against human A2780 cells after 48 hrs by SRB assay
    Anticancer activity against human A2780 cells after 48 hrs by SRB assay
    		[PMID: 20557981]
    A2780 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B based ELISA
    Cytotoxicity against human A2780 cells after 48 hrs by sulforhodamine B based ELISA
    		[PMID: 21402478]
    A2780 IC50
    0.5 μM
    Compound: Adriamycin
    Cytotoxicity against human A2780 cells after 48 hrs by MTT assay
    Cytotoxicity against human A2780 cells after 48 hrs by MTT assay
    		[PMID: 30137985]
    A2780 IC50
    2.03 μM
    Compound: ADM
    Antiproliferative activity against human A2780 cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A2780 cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 35282680]
    A2780 IC50
    2.69 μM
    Compound: ADM
    Antiproliferative activity against human paclitaxel-resistant A2780/TAX cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human paclitaxel-resistant A2780/TAX cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 35282680]
    A498 ED50
    3.5 μM
    Compound: Adriamycin
    Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined
    Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined
    		[PMID: 10091695]
    A549 EC50
    0.04 μM
    Compound: doxorubicin HCl
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 12027739]
    A549 ED50
    1.01 μg/mL
    Compound: Adriamycin
    Anticancer activity against human A549 cells
    Anticancer activity against human A549 cells
    		[PMID: 35367708]
    A549 ED50
    6.2 μM
    Compound: Adriamycin
    Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined
    Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined
    		[PMID: 10091695]
    A549 GI50
    0.06 μM
    Compound: doxorubicin hydrochloride
    Antitumor activity against human A549 cells after 72 hrs by SRB assay
    Antitumor activity against human A549 cells after 72 hrs by SRB assay
    		[PMID: 21718029]
    A549 GI50
    0.13 μM
    Compound: ADR
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21194809]
    A549 GI50
    60.3 nM
    Compound: Doxorubicin HCl
    Growth inhibition of human A549 cells after 72 hrs by SRB assay
    Growth inhibition of human A549 cells after 72 hrs by SRB assay
    		[PMID: 22607205]
    A549 GI50
    7.25 mM
    Compound: Adriamycin
    Growth inhibition of human A549 cells after 48 hrs by MTT assay
    Growth inhibition of human A549 cells after 48 hrs by MTT assay
    		[PMID: 32631569]
    A549 GI50
    7.25 μM
    Compound: ADR
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    		[PMID: 20444601]
    A549 GI50
    7.25 μM
    Compound: ADR
    Cytotoxicity against human A549 cells by sulforhodamine B method
    Cytotoxicity against human A549 cells by sulforhodamine B method
    		[PMID: 21459581]
    A549 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    		[PMID: 20554354]
    A549 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B based ELISA
    Cytotoxicity against human A549 cells after 48 hrs by sulforhodamine B based ELISA
    		[PMID: 21402478]
    A549 IC50
    0.002 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as decrease in cell viability by MTT assay
    Cytotoxicity against human A549 cells assessed as decrease in cell viability by MTT assay
    		[PMID: 29489361]
    A549 IC50
    0.025 μg/mL
    Compound: adriamycin HCl
    Antitumor activity against human A549 cells
    Antitumor activity against human A549 cells
    		[PMID: 10579858]
    A549 IC50
    0.04 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay
    		10.1039/C5MD00289C
    A549 IC50
    0.1 μM
    Compound: ADM
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 28749671]
    A549 IC50
    0.1 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    		[PMID: 25259515]
    A549 IC50
    0.1 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    		[PMID: 30049584]
    A549 IC50
    0.12 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 30222343]
    A549 IC50
    0.14 μM
    Compound: ADR
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 30006167]
    A549 IC50
    0.15 μM
    Compound: Adriamycin
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth
    		[PMID: 35931243]
    A549 IC50
    0.15 μg/mL
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human A549 cells
    Cytotoxicity against human A549 cells
    		[PMID: 9214732]
    A549 IC50
    0.16 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    		[PMID: 29407953]
    A549 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 24 hrs by sulforhodamine B assay
    Cytotoxicity against human A549 cells after 24 hrs by sulforhodamine B assay
    		[PMID: 28418245]
    A549 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 24 hrs by SRB method
    Cytotoxicity against human A549 cells after 24 hrs by SRB method
    		[PMID: 31904949]
    A549 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 34282909]
    A549 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth by CCK-8 assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth by CCK-8 assay
    		[PMID: 36583957]
    A549 IC50
    0.2 μM
    Compound: Dox
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 26506221]
    A549 IC50
    0.2 μM
    Compound: adriamycin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 23806071]
    A549 IC50
    0.29 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 34165979]
    A549 IC50
    0.3 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    Cytotoxicity against human A549 cells after 48 hrs by SRB assay
    		[PMID: 27462726]
    A549 IC50
    0.31 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition
    Cytotoxicity against human A549 cells assessed as cell growth inhibition
    		[PMID: 33333398]
    A549 IC50
    0.329 μM
    Compound: Doxorubicin HCl
    Antiproliferative activity against Homo sapiens (human) A549 cells after 72 hr by SRB assay
    Antiproliferative activity against Homo sapiens (human) A549 cells after 72 hr by SRB assay
    		10.1007/s00044-012-0443-x
    A549 IC50
    0.329 μM
    Compound: Doxorubicin HCl
    Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
    		[PMID: 22748378]
    A549 IC50
    0.33 μM
    Compound: DOX
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    Cytotoxicity against human A549 cells after 72 hrs by SRB assay
    		[PMID: 22574992]
    A549 IC50
    0.33 μM
    Compound: DOX
    Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 24686017]
    A549 IC50
    0.33 μM
    Compound: Doxorubicin HCl
    Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by SRB assay
    Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by SRB assay
    		[PMID: 24686018]
    A549 IC50
    0.4 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells measured after 72 hrs by CCK8 assay
    Cytotoxicity against human A549 cells measured after 72 hrs by CCK8 assay
    		[PMID: 31117522]
    A549 IC50
    0.4 μM
    Compound: Adriamycin
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
    		[PMID: 35121401]
    A549 IC50
    0.41 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay
    		[PMID: 21192108]
    A549 IC50
    0.44 μM
    Compound: Adr
    Cytotoxicity in human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK-8 assay
    Cytotoxicity in human A549 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK-8 assay
    		[PMID: 31184894]
    A549 IC50
    0.481 μM
    Compound: Adr
    Cytotoxicity against human A549 cells by SRB assay
    Cytotoxicity against human A549 cells by SRB assay
    		[PMID: 29182349]
    A549 IC50
    0.49 μM
    Compound: ADR
    Antiproliferative activity against human A549 cells incubated for 72 hrs by SRB method
    Antiproliferative activity against human A549 cells incubated for 72 hrs by SRB method
    		[PMID: 39054645]
    A549 IC50
    0.5 μM
    Compound: DOX.HCl
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 28445049]
    A549 IC50
    0.54 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 21123066]
    A549 IC50
    0.69 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 34081476]
    A549 IC50
    0.7 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 32293887]
    A549 IC50
    0.7 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 37947788]
    A549 IC50
    0.78 μM
    Compound: Adriamycin
    Anticancer activity against human A549 cells assessed as inhibition of cell proliferation
    Anticancer activity against human A549 cells assessed as inhibition of cell proliferation
    		[PMID: 32527548]
    A549 IC50
    0.78 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 33689875]
    A549 IC50
    0.85 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition by SRB assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition by SRB assay
    		[PMID: 34762434]
    A549 IC50
    0.9 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 34176266]
    A549 IC50
    1.03 μM
    Compound: ADM
    Antiproliferative activity against human A549 cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 35282680]
    A549 IC50
    1.13 μM
    Compound: ADR
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay
    		[PMID: 30837097]
    A549 IC50
    1.2 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as cell viability inhibition for 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell viability inhibition for 48 hrs by MTT assay
    		[PMID: 33913326]
    A549 IC50
    1.2 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 34797067]
    A549 IC50
    1.3 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 29286660]
    A549 IC50
    1.3 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		[PMID: 30137985]
    A549 IC50
    1.45 μM
    Compound: ADR
    Antiproliferative activity in human A549 cells after 48 hrs by MTT assay
    Antiproliferative activity in human A549 cells after 48 hrs by MTT assay
    		[PMID: 28570977]
    A549 IC50
    1.65 μM
    Compound: ADR
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 30677614]
    A549 IC50
    1.7 μM
    Compound: ADR
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 33097300]
    A549 IC50
    1.8 μM
    Compound: Adriamycin
    Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31268321]
    A549 IC50
    12.5 μM
    Compound: ADM
    Antiproliferative activity against human adriamycin-resistant A549/ADR cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human adriamycin-resistant A549/ADR cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 35282680]
    A549 IC50
    152 nM
    Compound: Adriamycin
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs in presence of (R)-4-((3,4-dibenzyl-2,5-dioxopiperazin-1-yl)methyl)-N-hydroxybenzamide by alamar blue assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs in presence of (R)-4-((3,4-dibenzyl-2,5-dioxopiperazin-1-yl)methyl)-N-hydroxybenzamide by alamar blue assay
    		[PMID: 31865013]
    A549 IC50
    2.19 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as inhibition of proliferation incubated for 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as inhibition of proliferation incubated for 72 hrs by MTT assay
    		[PMID: 34237623]
    A549 IC50
    2.3 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 33301677]
    A549 IC50
    2.36 μM
    Compound: Adriamycin
    Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Anticancer activity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 32485531]
    A549 IC50
    2.8 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 23477504]
    A549 IC50
    2.9 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 27704808]
    A549 IC50
    2.9 μM
    Compound: Adriamycin
    Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31117521]
    A549 IC50
    23.71 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    		[PMID: 25226363]
    A549 IC50
    255 nM
    Compound: Adriamycin
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue assay
    Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by alamar blue assay
    		[PMID: 31865013]
    A549 IC50
    4.3 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells by MTT assay
    Cytotoxicity against human A549 cells by MTT assay
    		[PMID: 25304898]
    A549 IC50
    5 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human A549 cells incubated for 48 hrs by MTT assay
    		[PMID: 32394716]
    A549 IC50
    5.92 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as cell viability by MTT assay
    Cytotoxicity against human A549 cells assessed as cell viability by MTT assay
    		[PMID: 38387332]
    A549 IC50
    8.5 μM
    Compound: Doxorubicin HCl
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
    		[PMID: 29884536]
    A549 IC50
    < 1 μM
    Compound: Adriamycin
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 31804070]
    A549/TR IC50
    42.57 μM
    Compound: ADR
    Cytotoxicity against human A549/TAX cells after 72 hrs by MTT assay
    Cytotoxicity against human A549/TAX cells after 72 hrs by MTT assay
    		[PMID: 30677614]
    ACHN GI50
    0.07 μM
    Compound: Adriamycin
    Cytotoxicity against human ACHN cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human ACHN cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay
    		[PMID: 29878761]
    ACHN GI50
    0.07 μM
    Compound: Adriamycin
    Growth inhibition of human ACHN cells by SRB assay
    Growth inhibition of human ACHN cells by SRB assay
    		[PMID: 36040099]
    ACHN GI50
    0.13 μM
    Compound: ADR
    Cytotoxicity against human ACHN cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Cytotoxicity against human ACHN cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 31668073]
    ACHN IC50
    0.17 μM
    Compound: ADR
    Cytotoxicity against human ACHN cells assessed as cell growth inhibition incubated for 48 hrs by SRB method
    Cytotoxicity against human ACHN cells assessed as cell growth inhibition incubated for 48 hrs by SRB method
    		[PMID: 35302779]
    ACHN IC50
    0.26 μM
    Compound: Adriamycin
    Anti-proliferative activity against human ACHN cells by XTT assay
    Anti-proliferative activity against human ACHN cells by XTT assay
    		[PMID: 25442319]
    AG1523 IC50
    0.396 μM
    Compound: Doxorubicin Hydrochloride
    Cytotoxicity against human AG1523 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human AG1523 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 37729693]
    AG1523 IC50
    0.4 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human AG01523 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human AG01523 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33774342]
    ASPC1 IC50
    0.2 μM
    Compound: ADM
    Cytotoxicity against human ASPC1 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human ASPC1 cells assessed as reduction in cell viability by SRB assay
    		[PMID: 35993848]
    ASPC1 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human ASPC1 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human ASPC1 cells assessed as reduction in cell viability by SRB assay
    		[PMID: 32840364]
    ASPC1 IC50
    0.21 μM
    Compound: Adriamycin
    Cytotoxicity against human ASPC1 cells by SRB assay
    Cytotoxicity against human ASPC1 cells by SRB assay
    		[PMID: 38662578]
    ASPC1 IC50
    0.3 μM
    Compound: ADM
    Cytotoxicity against human ASPC1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    Cytotoxicity against human ASPC1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    		[PMID: 35380848]
    ASPC1 IC50
    1.6 μM
    Compound: Adriamycin
    Cytotoxicity against human Aspc-1 cells after 72 hrs under normoxic condition by MTT assay
    Cytotoxicity against human Aspc-1 cells after 72 hrs under normoxic condition by MTT assay
    		[PMID: 29656202]
    ASPC1 IC50
    2 μM
    Compound: Adriamycin
    Cytotoxicity against human Aspc-1 cells after 72 hrs under hypoxic condition by MTT assay
    Cytotoxicity against human Aspc-1 cells after 72 hrs under hypoxic condition by MTT assay
    		[PMID: 29656202]
    ASPC1 IC50
    < 5 μM
    Compound: Adriamycin
    Antiproliferative activity against human ASPC1 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    Antiproliferative activity against human ASPC1 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    		[PMID: 35586422]
    B16 IC50
    6.4 μM
    Compound: Adriamycin
    Growth inhibition of mouse B16 cells by MTT method
    Growth inhibition of mouse B16 cells by MTT method
    		[PMID: 25611131]
    B16-BL6 EC50
    0.11 μM
    Compound: doxorubicin HCl
    Antiproliferative activity against mouse B16-BL6 cells after 72 hrs by MTT assay
    Antiproliferative activity against mouse B16-BL6 cells after 72 hrs by MTT assay
    		[PMID: 12027739]
    B16-BL6 IC50
    0.2 μM
    Compound: Doxorubicin HCl
    Antiproliferative activity against mouse B16-BL6 cells assessed as cell viability after 72 hrs by MTT assay
    Antiproliferative activity against mouse B16-BL6 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 11575942]
    B16-F10 GI50
    0.22 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against mouse B16F10 cells assessed as growth inhibition by SRB assay
    Cytotoxicity against mouse B16F10 cells assessed as growth inhibition by SRB assay
    		[PMID: 24507920]
    BALB/3T3 IC50
    1.078 μM
    Compound: Doxorubicin HCl
    Cytotoxicity against Mus musculus (mouse) BALB/3T3 cells after 72 hr by SRB assay
    Cytotoxicity against Mus musculus (mouse) BALB/3T3 cells after 72 hr by SRB assay
    		10.1007/s00044-012-0443-x
    BALB/3T3 IC50
    1.078 μM
    Compound: Doxorubicin HCl
    Antiproliferative activity against mouse BALB/3T3 cells after 72 hrs by SRB assay
    Antiproliferative activity against mouse BALB/3T3 cells after 72 hrs by SRB assay
    		[PMID: 22748378]
    BALB/3T3 IC50
    1.08 μM
    Compound: DOX
    Cytotoxicity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against mouse BALB/3T3 cells assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 24686017]
    BALB/3T3 IC50
    1.08 μM
    Compound: Doxorubicin HCl
    Cytotoxicity against mouse BALB/3T3 cells assessed as cell viability after 72 hrs by SRB assay
    Cytotoxicity against mouse BALB/3T3 cells assessed as cell viability after 72 hrs by SRB assay
    		[PMID: 24686018]
    BGC-823 IC50
    0.01 μM
    Compound: Doxorubicin.HCl
    Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay
    Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay
    		[PMID: 23131338]
    BGC-823 IC50
    0.76 μM
    Compound: adriamycin
    Cytotoxic activity against human BGC823 cells by MTT method
    Cytotoxic activity against human BGC823 cells by MTT method
    		[PMID: 25739048]
    BGC-823 IC50
    1.33 μM
    Compound: Adriamycin
    Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay
    Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay
    		[PMID: 21123066]
    BGC-823 IC50
    1.48 μM
    Compound: Adriamycin
    Cytotoxicity against human BGC823 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human BGC823 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 26933756]
    BGC-823 IC50
    1.5 μM
    Compound: Adriamycin
    Cytotoxicity against human BGC823 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human BGC823 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay
    		[PMID: 28206772]
    BGC-823 IC50
    < 1 μM
    Compound: Adriamycin
    Cytotoxicity against human BGC823 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    Cytotoxicity against human BGC823 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    		[PMID: 28757067]
    BGC-823 IC50
    < 1.3 μM
    Compound: Adriamycin
    Cytotoxicity against human BGC823 cells by MTT assay
    Cytotoxicity against human BGC823 cells by MTT assay
    		[PMID: 21875764]
    BT-474 IC50
    3.2 μM
    Compound: Adriamycin
    Antiproliferative activity against human BT474 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human BT474 cells after 72 hrs by CCK8 assay
    		[PMID: 26988802]
    BXPC-3 IC50
    0.32 μM
    Compound: ADR
    Antiproliferative activity against human BXPC-3 cells incubated for 72 hrs by SRB assay
    Antiproliferative activity against human BXPC-3 cells incubated for 72 hrs by SRB assay
    		[PMID: 39054645]
    Bcap37 IC50
    0.94 μM
    Compound: ADM
    Growth inhibition of human Bcap37 cells after 72 hrs by MTT assay
    Growth inhibition of human Bcap37 cells after 72 hrs by MTT assay
    		[PMID: 25064351]
    Bcap37 IC50
    1.9 μM
    Compound: ADM
    Cytotoxicity against human Bcap37 cells
    Cytotoxicity against human Bcap37 cells
    		[PMID: 31129455]
    Bel-7402 IC50
    0.274 μM
    Compound: ADR
    Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
    Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
    		[PMID: 30530194]
    Bel-7402 IC50
    0.274 μM
    Compound: ADR
    Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33676300]
    Bel-7402 IC50
    0.3 μM
    Compound: Adriamycin
    Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability by SRB assay
    		[PMID: 32840364]
    Bel-7402 IC50
    0.369 nM
    Compound: Adriamycin
    Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 35152092]
    Bel-7402 IC50
    0.4 μM
    Compound: Adriamycin
    Cytotoxicity against human Bel7402 cells after 24 hrs by SRB method
    Cytotoxicity against human Bel7402 cells after 24 hrs by SRB method
    		[PMID: 31904949]
    Bel-7402 IC50
    0.73 μM
    Compound: ADR
    Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
    Antiproliferative activity against human Bel7402 cells after 72 hrs by MTT assay
    		[PMID: 30006167]
    Bel-7402 IC50
    0.73 μM
    Compound: ADR
    Antiproliferative activity against human Bel7402 incubated for 72 hrs by MTT assay
    Antiproliferative activity against human Bel7402 incubated for 72 hrs by MTT assay
    		[PMID: 31553932]
    Bel-7402 IC50
    0.83 μM
    Compound: Adriamycin
    Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 27158140]
    Bel-7402 IC50
    1.732 μM
    Compound: ADR
    Antiproliferative activity against ADR-resistant human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against ADR-resistant human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33676300]
    Bel-7402 IC50
    11.7 μM
    Compound: Adriamycin
    Cytotoxicity against human Bel7402 cells by MTT assay
    Cytotoxicity against human Bel7402 cells by MTT assay
    		[PMID: 25304898]
    Bel-7402 IC50
    128 μM
    Compound: Adriamycin
    Cytotoxicity against human Bel-7402 cells assessed as inhibition of proliferation incubated for 72 hrs by MTT assay
    Cytotoxicity against human Bel-7402 cells assessed as inhibition of proliferation incubated for 72 hrs by MTT assay
    		[PMID: 34237623]
    Bel7402/5-FU IC50
    10.95 μM
    Compound: ADR
    Cytotoxicity against human Bel7402/5-FU cells after 72 hrs by MTT assay
    Cytotoxicity against human Bel7402/5-FU cells after 72 hrs by MTT assay
    		[PMID: 30677614]
    Bel7402/5-FU IC50
    8.36 μM
    Compound: ADR
    Antiproliferative activity against human Bel7402/5-FU incubated for 72 hrs by MTT assay
    Antiproliferative activity against human Bel7402/5-FU incubated for 72 hrs by MTT assay
    		[PMID: 31553932]
    C6 IC50
    0.06 μM
    Compound: ADR
    Antiproliferative activity against rat C6 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against rat C6 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31977207]
    CCRF-CEM GI50
    0.181 μg/mL
    Compound: ADR
    Antitumor activity against human CCRF-CEM cells
    Antitumor activity against human CCRF-CEM cells
    		[PMID: 20045644]
    CCRF-CEM IC50
    0.15 μM
    Compound: Dox
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by Alamar blue assay
    Cytotoxicity against human CCRF-CEM cells after 48 hrs by Alamar blue assay
    		[PMID: 25064348]
    COLO 205 GI50
    0.13 μM
    Compound: ADR
    Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay
    Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay
    		[PMID: 20554354]
    COLO 205 GI50
    0.14 μM
    Compound: ADR
    Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay
    Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay
    		[PMID: 20444601]
    COLO 205 GI50
    0.14 μM
    Compound: ADR
    Cytotoxicity against human COLO205 cells by sulforhodamine B method
    Cytotoxicity against human COLO205 cells by sulforhodamine B method
    		[PMID: 21459581]
    COLO 205 GI50
    0.523 μg/mL
    Compound: ADR
    Antitumor activity against human COLO205 cells
    Antitumor activity against human COLO205 cells
    		[PMID: 20045644]
    COLO 205 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human COLO205 cells after 48 hrs by sulforhodamine B based ELISA
    Cytotoxicity against human COLO205 cells after 48 hrs by sulforhodamine B based ELISA
    		[PMID: 21402478]
    COLO 205 IC50
    5.1 μM
    Compound: ADR
    Cytotoxicity against human COLO205 assessed as inhibition of cell growth
    Cytotoxicity against human COLO205 assessed as inhibition of cell growth
    		[PMID: 21144748]
    CWR22R IC50
    < 1 μM
    Compound: Adriamycin
    Cytotoxicity against human 22Rv1 cells by MTT assay
    Cytotoxicity against human 22Rv1 cells by MTT assay
    		[PMID: 20627721]
    CWR22R IC50
    < 1.3 μM
    Compound: Adriamycin
    Cytotoxicity against human 22Rv1 cells by MTT assay
    Cytotoxicity against human 22Rv1 cells by MTT assay
    		[PMID: 21875764]
    Caco-2 IC50
    0.72 μM
    Compound: Adriamycin
    Anticancer activity against human Caco2 cells assessed as inhibition of cell proliferation
    Anticancer activity against human Caco2 cells assessed as inhibition of cell proliferation
    		[PMID: 32527548]
    Caco-2 IC50
    0.97 μM
    Compound: Adriamycin
    Cytotoxicity against human Caco2 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human Caco2 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 26933756]
    DU-145 IC50
    0.21 μM
    Compound: Doxorubicin.HCl
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 30223117]
    DU-145 IC50
    0.52 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 48 hrs by CCK8 assay
    Cytotoxicity against human DU145 cells after 48 hrs by CCK8 assay
    		[PMID: 26945111]
    DU-145 IC50
    0.52 μM
    Compound: Adriamycin
    Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay
    		[PMID: 27643560]
    DU-145 IC50
    0.87 μM
    Compound: Adriamycin
    Antiproliferative activity against human DU145 cells measured after 72 hrs by EZ-Cytox assay
    Antiproliferative activity against human DU145 cells measured after 72 hrs by EZ-Cytox assay
    		[PMID: 31398033]
    DU-145 IC50
    1 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 2 days by automatic ELISA reader system
    Cytotoxicity against human DU145 cells after 2 days by automatic ELISA reader system
    		[PMID: 20392646]
    DU-145 IC50
    1.02 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells incubated from day 2 to day 4 by CCK8 assay
    Cytotoxicity against human DU145 cells incubated from day 2 to day 4 by CCK8 assay
    		[PMID: 26022080]
    DU-145 IC50
    1.19 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 48 hrs by MTT assay
    		[PMID: 20093033]
    DU-145 IC50
    1.3 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 3 days
    Cytotoxicity against human DU145 cells after 3 days
    		[PMID: 19954977]
    DU-145 IC50
    1.4 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 4 days by MTT assay
    Cytotoxicity against human DU145 cells after 4 days by MTT assay
    		[PMID: 20619511]
    DU-145 IC50
    1.5 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 4 days by ELISA reader assay
    Cytotoxicity against human DU145 cells after 4 days by ELISA reader assay
    		[PMID: 19939682]
    DU-145 IC50
    1.59 μM
    Compound: Adriamycin
    Antiproliferative activity against human DU145 cells measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human DU145 cells measured after 72 hrs by CCK8 assay
    		[PMID: 27654394]
    DU-145 IC50
    1.98 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells in presence of 10% fetal bovine serum
    Cytotoxicity against human DU145 cells in presence of 10% fetal bovine serum
    		[PMID: 20188578]
    DU-145 IC50
    2.47 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 2 days
    Cytotoxicity against human DU145 cells after 2 days
    		[PMID: 21419530]
    DU-145 IC50
    2.54 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells by MTT assay
    Cytotoxicity against human DU145 cells by MTT assay
    		[PMID: 19836231]
    DU-145 IC50
    2.99 μM
    Compound: Adriamycin
    Antiproliferative activity against human DU-145 cells after 72 hrs by EZ-Cytox colorimetric assay
    Antiproliferative activity against human DU-145 cells after 72 hrs by EZ-Cytox colorimetric assay
    		[PMID: 34678573]
    DU-145 IC50
    21.45 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
    Cytotoxicity against human DU145 cells after 24 hrs by MTT assay
    		[PMID: 25226363]
    DU-145 IC50
    3.48 μM
    Compound: Adriamycin
    Antiproliferative activity against human DU-145 cells assessed as inhibition of cell proliferation incubated for 72 hrs by WST assay
    Antiproliferative activity against human DU-145 cells assessed as inhibition of cell proliferation incubated for 72 hrs by WST assay
    		[PMID: 36493620]
    DU-145 IC50
    3.89 μM
    Compound: Adriamycin
    Cytotoxicity against human DU145 cells after 4 days by CCK-8 assay
    Cytotoxicity against human DU145 cells after 4 days by CCK-8 assay
    		[PMID: 25062006]
    DU-145 IC50
    4.88 μM
    Compound: ADM
    Cytotoxicity against human DU145 cells after 72 hrs by cell counting kit-8 analysis
    Cytotoxicity against human DU145 cells after 72 hrs by cell counting kit-8 analysis
    		[PMID: 29174815]
    DU-145 IC50
    5.85 μM
    Compound: Adriamycin
    Antiproliferative activity against human DU-145 cells assessed as inhibition of cell proliferation
    Antiproliferative activity against human DU-145 cells assessed as inhibition of cell proliferation
    		[PMID: 35123005]
    FHC IC50
    0.057 μM
    Compound: ADR
    Cytotoxicity against human FHC cells
    Cytotoxicity against human FHC cells
    		[PMID: 30006167]
    H69AR IC50
    15.1 μM
    Compound: ADM
    Cytotoxicity against human H69AR cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human H69AR cells assessed as reduction in cell viability by SRB assay
    		[PMID: 35993848]
    H69AR IC50
    15.12 μM
    Compound: Adriamycin
    Antiproliferative activity against human NCI-H69AR cells by SRB assay
    Antiproliferative activity against human NCI-H69AR cells by SRB assay
    		[PMID: 38964518]
    HBL-100 IC50
    0.14 mg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HBL100 cells after 24 hrs by MTT assay
    Cytotoxicity against human HBL100 cells after 24 hrs by MTT assay
    		[PMID: 22142614]
    HCC70 IC50
    1.45 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCC70 cells measured after 72 hrs by Ez-cytox assay
    Antiproliferative activity against human HCC70 cells measured after 72 hrs by Ez-cytox assay
    		[PMID: 31398033]
    HCT-116 IC50
    0.0012 μM
    Compound: Adiramycin
    Anticancer activity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay
    Anticancer activity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay
    		[PMID: 33940466]
    HCT-116 IC50
    0.01 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT116 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay
    		10.1039/C5MD00289C
    HCT-116 IC50
    0.06 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 24 hrs by SRB assay
    Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 24 hrs by SRB assay
    		[PMID: 31436991]
    HCT-116 IC50
    0.1 μM
    Compound: ADR
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 35762988]
    HCT-116 IC50
    0.1 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by SRB assay
    		[PMID: 32840364]
    HCT-116 IC50
    0.16 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 34165979]
    HCT-116 IC50
    0.2 μM
    Compound: ADM
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 29985604]
    HCT-116 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells after 24 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT116 cells after 24 hrs by sulforhodamine B assay
    		[PMID: 28418245]
    HCT-116 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells after 24 hrs by SRB method
    Cytotoxicity against human HCT116 cells after 24 hrs by SRB method
    		[PMID: 31904949]
    HCT-116 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability after 48 hrs by SRB assay
    		[PMID: 32880456]
    HCT-116 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 34282909]
    HCT-116 IC50
    0.2 μM
    Compound: Dox
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 26506221]
    HCT-116 IC50
    0.21 μM
    Compound: ADR
    Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by SRB method
    Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by SRB method
    		[PMID: 39054645]
    HCT-116 IC50
    0.39 μM
    Compound: Doxorubicin HCl
    Antiproliferative activity against Homo sapiens (human) HCT116 cells after 72 hr by SRB assay
    Antiproliferative activity against Homo sapiens (human) HCT116 cells after 72 hr by SRB assay
    		10.1007/s00044-012-0443-x
    HCT-116 IC50
    0.39 μM
    Compound: Doxorubicin HCl
    Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay
    		[PMID: 22748378]
    HCT-116 IC50
    0.39 μM
    Compound: Doxorubicin HCl
    Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by SRB assay
    Cytotoxicity against human HCT116 cells assessed as cell viability after 72 hrs by SRB assay
    		[PMID: 24686018]
    HCT-116 IC50
    0.41 μM
    Compound: ADR
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 30006167]
    HCT-116 IC50
    0.41 μM
    Compound: adriamycin
    Cytotoxic activity against human HCT116 cells by MTT method
    Cytotoxic activity against human HCT116 cells by MTT method
    		[PMID: 25739048]
    HCT-116 IC50
    1.1 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells after 3 days
    Cytotoxicity against human HCT116 cells after 3 days
    		[PMID: 19954977]
    HCT-116 IC50
    1.4 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay
    		[PMID: 28206772]
    HCT-116 IC50
    2.31 μM
    Compound: ADM
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    		[PMID: 29232583]
    HCT-116 IC50
    2.9 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 34176266]
    HCT-116 IC50
    3.03 μM
    Compound: Dox
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
    		[PMID: 22318158]
    HCT-116 IC50
    4 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells after 4 days by MTT assay
    Cytotoxicity against human HCT116 cells after 4 days by MTT assay
    		[PMID: 20619511]
    HCT-116 IC50
    5 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 26810315]
    HCT-116 IC50
    5 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 27318975]
    HCT-116 IC50
    6.81 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT116 cells after 2 days
    Cytotoxicity against human HCT116 cells after 2 days
    		[PMID: 21419530]
    HCT-116 IC50
    > 1.25 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    		[PMID: 35586422]
    HCT-15 GI50
    0.05 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human HCT15 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay
    		[PMID: 29878761]
    HCT-15 GI50
    0.09 μM
    Compound: Adriamycin
    Growth inhibition of human HCT-15 cells by SRB assay
    Growth inhibition of human HCT-15 cells by SRB assay
    		[PMID: 36040099]
    HCT-15 GI50
    0.14 μM
    Compound: ADR
    Cytotoxicity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Cytotoxicity against human HCT15 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 31668073]
    HCT-15 GI50
    80 μg/mL
    Compound: Adriamycin
    Growth inhibition of human HCT-15 cells incubated for 48 hrs by SRB assay
    Growth inhibition of human HCT-15 cells incubated for 48 hrs by SRB assay
    		[PMID: 38830427]
    HCT-15 IC50
    0.09 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells after 3 days by CCK8 assay
    Cytotoxicity against human HCT15 cells after 3 days by CCK8 assay
    		[PMID: 26927425]
    HCT-15 IC50
    0.17 μM
    Compound: ADR
    Cytotoxicity against human HCT-15 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method
    Cytotoxicity against human HCT-15 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method
    		[PMID: 35302779]
    HCT-15 IC50
    0.43 μM
    Compound: Adriamycin
    Anti-proliferative activity against human HCT15 cells by XTT assay
    Anti-proliferative activity against human HCT15 cells by XTT assay
    		[PMID: 25442319]
    HCT-15 IC50
    0.47 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells assessed as reduction in cell growth after 72 hrs by CCK8 assay
    Cytotoxicity against human HCT15 cells assessed as reduction in cell growth after 72 hrs by CCK8 assay
    		[PMID: 27484510]
    HCT-15 IC50
    0.51 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT15 cells incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human HCT15 cells incubated for 72 hrs by CCK8 assay
    		[PMID: 29402741]
    HCT-15 IC50
    0.51 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT15 cells after 72 hrs by EZ-CYTOX reagent based assay
    Antiproliferative activity against human HCT15 cells after 72 hrs by EZ-CYTOX reagent based assay
    		[PMID: 30262132]
    HCT-15 IC50
    0.73 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT15 cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human HCT15 cells after 72 hrs by CCK-8 assay
    		[PMID: 29510948]
    HCT-15 IC50
    0.74 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT15 cells measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human HCT15 cells measured after 72 hrs by CCK8 assay
    		[PMID: 27654394]
    HCT-15 IC50
    0.74 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT15 cells measured after 72 hrs by EZ-Cytox assay
    Antiproliferative activity against human HCT15 cells measured after 72 hrs by EZ-Cytox assay
    		[PMID: 31398033]
    HCT-15 IC50
    0.94 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
    		[PMID: 28633898]
    HCT-15 IC50
    1 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
    		[PMID: 28068603]
    HCT-15 IC50
    1.08 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
    		[PMID: 27643560]
    HCT-15 IC50
    1.2 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells after 2 days by automatic ELISA reader system
    Cytotoxicity against human HCT15 cells after 2 days by automatic ELISA reader system
    		[PMID: 20392646]
    HCT-15 IC50
    1.21 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells incubated from day 2 to day 4 by CCK8 assay
    Cytotoxicity against human HCT15 cells incubated from day 2 to day 4 by CCK8 assay
    		[PMID: 26022080]
    HCT-15 IC50
    1.23 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells after 48 hrs by CCK8 assay
    Cytotoxicity against human HCT15 cells after 48 hrs by CCK8 assay
    		[PMID: 26945111]
    HCT-15 IC50
    1.28 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
    		[PMID: 28384547]
    HCT-15 IC50
    1.28 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT-15 cells assessed as inhibition of cell proliferation
    Antiproliferative activity against human HCT-15 cells assessed as inhibition of cell proliferation
    		[PMID: 35123005]
    HCT-15 IC50
    1.89 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT-15 cells assessed as reduction in cell viability after 48 hrs by by Ez-cytoX based microplate reader method
    Antiproliferative activity against human HCT-15 cells assessed as reduction in cell viability after 48 hrs by by Ez-cytoX based microplate reader method
    		[PMID: 34597897]
    HCT-15 IC50
    136 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT-15 cells after 72 hrs by EZ-Cytox colorimetric assay
    Antiproliferative activity against human HCT-15 cells after 72 hrs by EZ-Cytox colorimetric assay
    		[PMID: 34678573]
    HCT-15 IC50
    2.12 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells after 4 days by ELISA reader assay
    Cytotoxicity against human HCT15 cells after 4 days by ELISA reader assay
    		[PMID: 19939682]
    HCT-15 IC50
    2.32 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells in presence of 10% fetal bovine serum
    Cytotoxicity against human HCT15 cells in presence of 10% fetal bovine serum
    		[PMID: 20188578]
    HCT-15 IC50
    2.59 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT15 cells after 4 days by CCK-8 assay
    Cytotoxicity against human HCT15 cells after 4 days by CCK-8 assay
    		[PMID: 25062006]
    HCT-15 IC50
    23 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human HCT15 cells after 72 hrs by CCK8 assay
    		[PMID: 26988802]
    HCT-15 IC50
    3.76 μM
    Compound: ADM
    Cytotoxicity against human HCT15 cells after 72 hrs by cell counting kit-8 analysis
    Cytotoxicity against human HCT15 cells after 72 hrs by cell counting kit-8 analysis
    		[PMID: 29174815]
    HCT-15 IC50
    5.56 μM
    Compound: Adriamycin
    Antiproliferative activity against human HCT-15 cells assessed as inhibition of cell proliferation incubated for 72 hrs by WST assay
    Antiproliferative activity against human HCT-15 cells assessed as inhibition of cell proliferation incubated for 72 hrs by WST assay
    		[PMID: 36493620]
    HCT-8 ED50
    0.3 μg/mL
    Compound: Adriamycin HCl
    Cytotoxicity against human HCT8 cells
    Cytotoxicity against human HCT8 cells
    		[PMID: 2095375]
    HCT-8 IC50
    0.3 μg/mL
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human HCT8 cells
    Cytotoxicity against human HCT8 cells
    		[PMID: 9214732]
    HCT-8 IC50
    21.6 μM
    Compound: ADM
    Antiproliferative activity against human vincristine-resistant HCT-8/VCR cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human vincristine-resistant HCT-8/VCR cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 35282680]
    HCT-8 IC50
    3.98 μM
    Compound: ADM
    Antiproliferative activity against human HCT-8 cells assessed as cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human HCT-8 cells assessed as cell viability incubated for 48 hrs by MTT assay
    		[PMID: 35282680]
    HCT-8 IC50
    < 1 μM
    Compound: Adriamycin
    Cytotoxicity against human HCT8 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    Cytotoxicity against human HCT8 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    		[PMID: 28757067]
    HEK293 IC50
    0.37 μM
    Compound: ADM
    Cytotoxicity against human HEK293 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    Cytotoxicity against human HEK293 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    		[PMID: 30827866]
    HEK293 IC50
    1.22 μM
    Compound: Adriamycin
    Cytotoxicity against HEK293 cells after 4 days by CCK-8 assay
    Cytotoxicity against HEK293 cells after 4 days by CCK-8 assay
    		[PMID: 25062006]
    HEK293 IC50
    4.96 μM
    Compound: Adriamycin
    Antiproliferative activity against HEK293 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against HEK293 cells after 72 hrs by CCK8 assay
    		[PMID: 27643560]
    HEL IC50
    0.24 μM
    Compound: ADR
    Cytotoxicity against HEL cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against HEL cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 38253024]
    HEp-2 IC50
    < 1 μM
    Compound: Adriamycin
    Cytotoxicity against human Hep2 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    Cytotoxicity against human Hep2 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    		[PMID: 28757067]
    HFL1 IC50
    2.31 μM
    Compound: Adriamycin
    Antiproliferative activity against HFL1 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against HFL1 cells after 72 hrs by CCK8 assay
    		[PMID: 27643560]
    HL-60 GI50
    0.02 μM
    Compound: Doxorubicin hydrochloride
    Growth inhibition of human HL60 cells measured after 3 days by trypan blue assay
    Growth inhibition of human HL60 cells measured after 3 days by trypan blue assay
    		[PMID: 29565129]
    HL-60 GI50
    0.413 μg/mL
    Compound: ADR
    Antitumor activity against human HL60 cells
    Antitumor activity against human HL60 cells
    		[PMID: 20045644]
    HL-60 IC50
    0.01 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 15387667]
    HL-60 IC50
    0.016 μM
    Compound: ADR
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 26832219]
    HL-60 IC50
    0.019 μM
    Compound: ADR
    Cytotoxicity against human HL60 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay
    Cytotoxicity against human HL60 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay
    		[PMID: 28068601]
    HL-60 IC50
    0.019 μM
    Compound: Adriamycin
    Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth by CCK-8 assay
    Cytotoxicity against human HL-60 cells assessed as inhibition of cell growth by CCK-8 assay
    		[PMID: 36583957]
    HL-60 IC50
    0.02 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 28418245]
    HL-60 IC50
    0.02 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 29286660]
    HL-60 IC50
    0.02 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 31904949]
    HL-60 IC50
    0.02 μM
    Compound: Adriamycin
    Cytotoxicity against human HL-60 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HL-60 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32880456]
    HL-60 IC50
    0.02 μM
    Compound: Adriamycin
    Cytotoxicity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
    Cytotoxicity against human HL-60 cells assessed as cell growth inhibition incubated for 72 hrs by CCK8 assay
    		[PMID: 34762434]
    HL-60 IC50
    0.02 μM
    Compound: Dox
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 26506221]
    HL-60 IC50
    0.04 μM
    Compound: Adriamycin
    Cytotoxicity against Homo sapiens (human) HL60 cells assessed as reduction in cell survival fraction after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HL60 cells assessed as reduction in cell survival fraction after 48 hr by MTT assay
    		10.1007/s00044-011-9703-4
    HL-60 IC50
    0.06 μM
    Compound: Adriamycin
    Cytotoxicity against human HL-60 cells assessed as cell growth inhibition
    Cytotoxicity against human HL-60 cells assessed as cell growth inhibition
    		[PMID: 33333398]
    HL-60 IC50
    0.067 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    		[PMID: 27462726]
    HL-60 IC50
    0.075 μM
    Compound: Adr
    Cytotoxicity in human HL60 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK-8 assay
    Cytotoxicity in human HL60 cells assessed as inhibition of cell viability incubated for 72 hrs by CCK-8 assay
    		[PMID: 31184894]
    HL-60 IC50
    0.076 μM
    Compound: Adr
    Cytotoxicity against human HL60 cells by MTT assay
    Cytotoxicity against human HL60 cells by MTT assay
    		[PMID: 29182349]
    HL-60 IC50
    0.08 μM
    Compound: 1
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 20133021]
    HL-60 IC50
    0.08 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells measured after 72 hrs by CCK8 assay
    Cytotoxicity against human HL60 cells measured after 72 hrs by CCK8 assay
    		[PMID: 31117522]
    HL-60 IC50
    0.1 μM
    Compound: 1
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    		[PMID: 20133021]
    HL-60 IC50
    0.1 μM
    Compound: adriamicin
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    		[PMID: 21090801]
    HL-60 IC50
    0.13 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 21192108]
    HL-60 IC50
    0.14 μM
    Compound: ADM
    Cytotoxicity against human HL60 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    Cytotoxicity against human HL60 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    		[PMID: 30827866]
    HL-60 IC50
    0.18 μM
    Compound: adriamycin
    Cytotoxicity against human HL60 cells by MTT assay
    Cytotoxicity against human HL60 cells by MTT assay
    		[PMID: 19962306]
    HL-60 IC50
    0.2 μM
    Compound: ADM
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
    		[PMID: 29985604]
    HL-60 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human HL60 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 27992183]
    HL-60 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human HL-60 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human HL-60 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 32840364]
    HL-60 IC50
    0.22 μM
    Compound: 1
    Cytotoxicity against human HL60 cells after 24 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 24 hrs by MTT assay
    		[PMID: 20133021]
    HL-60 IC50
    0.32 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells after 2 days
    Cytotoxicity against human HL60 cells after 2 days
    		[PMID: 21419530]
    HL-60 IC50
    0.7 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells after 2 days by automatic ELISA reader system
    Cytotoxicity against human HL60 cells after 2 days by automatic ELISA reader system
    		[PMID: 20392646]
    HL-60 IC50
    0.88 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells by MTT assay
    Cytotoxicity against human HL60 cells by MTT assay
    		[PMID: 19836231]
    HL-60 IC50
    0.94 μM
    Compound: Adriamycin
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    		[PMID: 20093033]
    HL60/ADR IC50
    4.3 μM
    Compound: Adriamycin
    Cytotoxicity against Homo sapiens (human) HL60/ADR cells assessed as reduction in cell survival fraction after 48 hr by MTT assay
    Cytotoxicity against Homo sapiens (human) HL60/ADR cells assessed as reduction in cell survival fraction after 48 hr by MTT assay
    		10.1007/s00044-011-9703-4
    HL60/ADR IC50
    4.89 μM
    Compound: ADR
    Cytotoxicity against human HL60/ADR cells after 72 hrs by MTT assay
    Cytotoxicity against human HL60/ADR cells after 72 hrs by MTT assay
    		[PMID: 26832219]
    HOP-62 GI50
    0.12 μM
    Compound: ADR
    Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay
    Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay
    		[PMID: 20554354]
    HOP-62 GI50
    0.14 mM
    Compound: Adriamycin
    Growth inhibition of human HOP62 cells after 48 hrs by MTT assay
    Growth inhibition of human HOP62 cells after 48 hrs by MTT assay
    		[PMID: 32631569]
    HOP-62 GI50
    0.14 μM
    Compound: ADR
    Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay
    Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay
    		[PMID: 20444601]
    HOP-62 GI50
    0.14 μM
    Compound: ADR
    Cytotoxicity against human HOP62 cells by sulforhodamine B method
    Cytotoxicity against human HOP62 cells by sulforhodamine B method
    		[PMID: 21459581]
    HOP-62 IC50
    5.4 μM
    Compound: ADR
    Cytotoxicity against human HOP62 assessed as inhibition of cell growth
    Cytotoxicity against human HOP62 assessed as inhibition of cell growth
    		[PMID: 21144748]
    HT-1080 EC50
    0.02 μM
    Compound: doxorubicin HCl
    Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay
    		[PMID: 12027739]
    HT-1080 ED50
    0.034 μg/mL
    Compound: doxorubicin HCl
    Cytotoxicity against human HT1080 cells after 24 hrs by MTT assay
    Cytotoxicity against human HT1080 cells after 24 hrs by MTT assay
    		[PMID: 9677271]
    HT-1080 IC50
    0.007 μM
    Compound: Doxorubicin Hydrochloride
    Cytotoxicity against human HT-1080 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human HT-1080 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 37729693]
    HT-1080 IC50
    0.008 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human HT-1080 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human HT-1080 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33774342]
    HT-1080 IC50
    0.012 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
    Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
    		[PMID: 15387667]
    HT-1080 IC50
    0.2 μM
    Compound: Doxorubicin HCl
    Antiproliferative activity against human HT1080 cells assessed as cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human HT1080 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 11575942]
    HT-1080 IC50
    0.38 μM
    Compound: Adriamycin
    Cytotoxicity against human HT1080 cells assessed as reduction cell viability after 72 hrs by WST8-based colorimetric analysis
    Cytotoxicity against human HT1080 cells assessed as reduction cell viability after 72 hrs by WST8-based colorimetric analysis
    		[PMID: 27332142]
    HT-1080 IC50
    4.7 μM
    Compound: ADR
    Cytotoxicity against human HT1080 assessed as inhibition of cell growth
    Cytotoxicity against human HT1080 assessed as inhibition of cell growth
    		[PMID: 21144748]
    HT-29 ED50
    3.7 μM
    Compound: Adriamycin
    Cytotoxicity against HT-29 cell line in the purdue cell culture screen was determined
    Cytotoxicity against HT-29 cell line in the purdue cell culture screen was determined
    		[PMID: 10091695]
    HT-29 GI50
    0.15 μM
    Compound: DOX HCl
    Growth inhibition against human HT-29 cells after 72 hrs by inverted microscopy
    Growth inhibition against human HT-29 cells after 72 hrs by inverted microscopy
    		[PMID: 23353738]
    HT-29 GI50
    0.15 μM
    Compound: doxorubicin hydrochloride
    Antitumor activity against human HT-29 cells after 72 hrs by SRB assay
    Antitumor activity against human HT-29 cells after 72 hrs by SRB assay
    		[PMID: 21718029]
    HT-29 GI50
    153 nM
    Compound: Doxorubicin HCl
    Growth inhibition of human HT-29 cells after 72 hrs by SRB assay
    Growth inhibition of human HT-29 cells after 72 hrs by SRB assay
    		[PMID: 22607205]
    HT-29 IC50
    0.559 μM
    Compound: Adr
    Cytotoxicity against human HT-29 cells by SRB assay
    Cytotoxicity against human HT-29 cells by SRB assay
    		[PMID: 29182349]
    HT-29 IC50
    0.58 mg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay
    		[PMID: 22142614]
    HT-29 IC50
    0.5 μg/mL
    Compound: adriamycin HCl
    Antitumor activity against human HT-29 cells
    Antitumor activity against human HT-29 cells
    		[PMID: 10579858]
    HT-29 IC50
    0.95 μM
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
    		[PMID: 20093033]
    HT-29 IC50
    1.46 μM
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 27318123]
    HT-29 IC50
    1.76 μM
    Compound: Adriamycin
    Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
    		[PMID: 28222318]
    HT-29 IC50
    1.8 μM
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 33301677]
    HT-29 IC50
    2.6 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human HT-29 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 34176266]
    HT-29 IC50
    3.8 μM
    Compound: Adriamycin
    Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31117521]
    HT-29 IC50
    3.8 μM
    Compound: Adriamycin
    Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31268321]
    HT-29 IC50
    3.9 μM
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells by MTT assay
    Cytotoxicity against human HT-29 cells by MTT assay
    		[PMID: 19836231]
    HT-29 IC50
    4.2 μM
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells by MTT assay
    Cytotoxicity against human HT-29 cells by MTT assay
    		[PMID: 20627721]
    HT-29 IC50
    4.2 μM
    Compound: Adriamycin
    Cytotoxicity against human HT-29 cells by MTT assay
    Cytotoxicity against human HT-29 cells by MTT assay
    		[PMID: 21875764]
    HUVEC IC50
    4.3 μM
    Compound: ADR
    Cytotoxicity against HUVEC assessed as reduction in cell viability by MTT assay
    Cytotoxicity against HUVEC assessed as reduction in cell viability by MTT assay
    		[PMID: 33097300]
    HeLa EC50
    0.02 μM
    Compound: doxorubicin HCl
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 12027739]
    HeLa GI50
    0.17 μM
    Compound: DOX HCl
    Growth inhibition against human HeLa cells after 72 hrs by inverted microscopy
    Growth inhibition against human HeLa cells after 72 hrs by inverted microscopy
    		[PMID: 23353738]
    HeLa GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay
    		[PMID: 27987486]
    HeLa GI50
    < 0.1 μM
    Compound: ADR
    Growth inhibition of human HeLa cells after 48 hrs by SRB assay
    Growth inhibition of human HeLa cells after 48 hrs by SRB assay
    		[PMID: 28188067]
    HeLa GI50
    < 0.1 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells
    Cytotoxicity against human HeLa cells
    		[PMID: 26725026]
    HeLa GI50
    < 80 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells
    Cytotoxicity against human HeLa cells
    		[PMID: 31926469]
    HeLa IC50
    0.1 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability by MTT assay
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability by MTT assay
    		[PMID: 29489361]
    HeLa IC50
    0.18 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 34165979]
    HeLa IC50
    0.3 μM
    Compound: ADM
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 28749671]
    HeLa IC50
    0.3 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 37947788]
    HeLa IC50
    0.31 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 30222343]
    HeLa IC50
    0.31 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 34081476]
    HeLa IC50
    0.43 μM
    Compound: ADM
    Cytotoxicity against human HeLa cells after 2 days by MTT assay
    Cytotoxicity against human HeLa cells after 2 days by MTT assay
    		[PMID: 21821321]
    HeLa IC50
    0.48 μM
    Compound: Adriamycin
    Anticancer activity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    Anticancer activity against human HeLa cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
    		[PMID: 32485531]
    HeLa IC50
    0.5 μM
    Compound: Adriamycin
    Growth inhibition of human HeLa cells after 72 hrs by MTT assay
    Growth inhibition of human HeLa cells after 72 hrs by MTT assay
    		[PMID: 26539973]
    HeLa IC50
    0.5 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability by SRB assay
    		[PMID: 27992183]
    HeLa IC50
    0.5 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 32293887]
    HeLa IC50
    0.5 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 38381613]
    HeLa IC50
    0.6 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 24 hrs by sulforhodamine B assay
    Cytotoxicity against human HeLa cells after 24 hrs by sulforhodamine B assay
    		[PMID: 28418245]
    HeLa IC50
    0.6 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells by SRB assay
    Cytotoxicity against human HeLa cells by SRB assay
    		[PMID: 29407953]
    HeLa IC50
    0.6 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 24 hrs by SRB method
    Cytotoxicity against human HeLa cells after 24 hrs by SRB method
    		[PMID: 31904949]
    HeLa IC50
    0.6 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by SRB assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by SRB assay
    		[PMID: 32880456]
    HeLa IC50
    0.6 μM
    Compound: adriamycin
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 23806071]
    HeLa IC50
    0.602 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 35152092]
    HeLa IC50
    0.69 μg/mL
    Compound: Dox
    Cytotoxicity against Homo sapiens (human) HeLa cells assessed as inhibition of cell viability by MTT assay
    Cytotoxicity against Homo sapiens (human) HeLa cells assessed as inhibition of cell viability by MTT assay
    		10.1007/s00044-013-0486-7
    HeLa IC50
    0.71 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 20093033]
    HeLa IC50
    0.72 μM
    Compound: adriamycin
    Cytotoxic activity against human HeLa cells by MTT method
    Cytotoxic activity against human HeLa cells by MTT method
    		[PMID: 25739048]
    HeLa IC50
    0.78 μM
    Compound: DOX
    Anticancer activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Anticancer activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 38389893]
    HeLa IC50
    0.8 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa cells measured after 72 hrs by EZ-Cytox assay
    Antiproliferative activity against human HeLa cells measured after 72 hrs by EZ-Cytox assay
    		[PMID: 31398033]
    HeLa IC50
    0.81 μg/mL
    Compound: Dox
    Cytotoxicity against Homo sapiens (human) HeLa cells assessed as inhibition of cell viability by SRB assay
    Cytotoxicity against Homo sapiens (human) HeLa cells assessed as inhibition of cell viability by SRB assay
    		10.1007/s00044-013-0486-7
    HeLa IC50
    0.82 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 3 days by CCK8 assay
    Cytotoxicity against human HeLa cells after 3 days by CCK8 assay
    		[PMID: 26927425]
    HeLa IC50
    0.88 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 48 hrs by CCK8 assay
    Cytotoxicity against human HeLa cells after 48 hrs by CCK8 assay
    		[PMID: 26945111]
    HeLa IC50
    0.88 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay
    		[PMID: 27643560]
    HeLa IC50
    1 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 2 days by automatic ELISA reader system
    Cytotoxicity against human HeLa cells after 2 days by automatic ELISA reader system
    		[PMID: 20392646]
    HeLa IC50
    1 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells assessed as inhibition of growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as inhibition of growth incubated for 72 hrs by MTT assay
    		[PMID: 28206772]
    HeLa IC50
    1.01 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells incubated from day 2 to day 4 by CCK8 assay
    Cytotoxicity against human HeLa cells incubated from day 2 to day 4 by CCK8 assay
    		[PMID: 26022080]
    HeLa IC50
    1.03 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by Ez-cytoX based microplate reader method
    Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by Ez-cytoX based microplate reader method
    		[PMID: 34597897]
    HeLa IC50
    1.06 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 27318123]
    HeLa IC50
    1.07 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth
    		[PMID: 35931243]
    HeLa IC50
    1.08 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells by MTT assay
    Cytotoxicity against human HeLa cells by MTT assay
    		[PMID: 19836231]
    HeLa IC50
    1.13 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 4 days by ELISA reader assay
    Cytotoxicity against human HeLa cells after 4 days by ELISA reader assay
    		[PMID: 19939682]
    HeLa IC50
    1.2 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay
    		[PMID: 28068603]
    HeLa IC50
    1.2 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay
    		[PMID: 28384547]
    HeLa IC50
    1.23 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 28222318]
    HeLa IC50
    1.3 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability by MTT assay
    		[PMID: 34176266]
    HeLa IC50
    1.32 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 2 days
    Cytotoxicity against human HeLa cells after 2 days
    		[PMID: 21419530]
    HeLa IC50
    1.35 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		[PMID: 21123066]
    HeLa IC50
    1.36 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa cells after 72 hrs by EZ-Cytox colorimetric assay
    Antiproliferative activity against human HeLa cells after 72 hrs by EZ-Cytox colorimetric assay
    		[PMID: 34678573]
    HeLa IC50
    1.4 μM
    Compound: Doxorubicin HCl
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
    		[PMID: 29884536]
    HeLa IC50
    1.5 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa cells incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human HeLa cells incubated for 72 hrs by CCK8 assay
    		[PMID: 29402741]
    HeLa IC50
    1.5 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa cells after 72 hrs by EZ-CYTOX reagent based assay
    Antiproliferative activity against human HeLa cells after 72 hrs by EZ-CYTOX reagent based assay
    		[PMID: 30262132]
    HeLa IC50
    1.6 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 3 days
    Cytotoxicity against human HeLa cells after 3 days
    		[PMID: 19954977]
    HeLa IC50
    1.7 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells assessed as reduction in cell growth after 72 hrs by CCK8 assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell growth after 72 hrs by CCK8 assay
    		[PMID: 27484510]
    HeLa IC50
    1.7 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay
    		[PMID: 29510948]
    HeLa IC50
    1.78 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells assessed as cell viability by MTT assay
    Cytotoxicity against human HeLa cells assessed as cell viability by MTT assay
    		[PMID: 38387332]
    HeLa IC50
    1.82 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells in presence of 10% fetal bovine serum
    Cytotoxicity against human HeLa cells in presence of 10% fetal bovine serum
    		[PMID: 20188578]
    HeLa IC50
    10.1 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells after 4 days by MTT assay
    Cytotoxicity against human HeLa cells after 4 days by MTT assay
    		[PMID: 20619511]
    HeLa IC50
    2.5 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 27318975]
    HeLa IC50
    2.77 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay
    		[PMID: 28633898]
    HeLa IC50
    231 nM
    Compound: adriamycin
    Cytotoxicity against wild type human HeLa cells by MTT assay
    Cytotoxicity against wild type human HeLa cells by MTT assay
    		[PMID: 16562842]
    HeLa IC50
    25.65 μM
    Compound: adriamycin
    Cytotoxicity against MDR1-G185 overexpressing human HeLa cells by MTT assay
    Cytotoxicity against MDR1-G185 overexpressing human HeLa cells by MTT assay
    		[PMID: 16562842]
    HeLa IC50
    5.04 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation
    Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation
    		[PMID: 35123005]
    HeLa IC50
    < 0.068 mg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
    		[PMID: 22142614]
    HeLa IC50
    < 0.1 μM
    Compound: Adiramycin
    Cytotoxicity against human HeLa cells by SRB method
    Cytotoxicity against human HeLa cells by SRB method
    		[PMID: 24951333]
    HeLa IC50
    < 1 μM
    Compound: Adriamycin
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    		[PMID: 28757067]
    HeLa IC50
    < 10 μM
    Compound: Adriamycin
    Anticancer activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Anticancer activity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 35694689]
    HeLa/Fucci2 IC50
    2 μM
    Compound: Adriamycin
    Antiproliferative activity against human HeLa/Fucci2 cells assessed as inhibition of cell viability incubated for 3 days by MTT assay
    Antiproliferative activity against human HeLa/Fucci2 cells assessed as inhibition of cell viability incubated for 3 days by MTT assay
    		[PMID: 31848114]
    HepG2 CC50
    127 μM
    Compound: ADR
    Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay
    Cytotoxicity against human HepG2 cells after 48 hrs by SRB assay
    		[PMID: 26675440]
    HepG2 GI50
    0.04 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by SRB assay
    		[PMID: 27598688]
    HepG2 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by SRB assay
    Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by SRB assay
    		10.1007/s00044-012-0423-1
    HepG2 IC50
    0.001 μM
    Compound: Adiramycin
    Anticancer activity against human HepG2 cells assessed as inhibition of cell growth by MTT assay
    Anticancer activity against human HepG2 cells assessed as inhibition of cell growth by MTT assay
    		[PMID: 33940466]
    HepG2 IC50
    0.036 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells by SRB assay
    Cytotoxicity against human HepG2 cells by SRB assay
    		[PMID: 29407953]
    HepG2 IC50
    0.1 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells assessed as decrease in cell viability by MTT assay
    Cytotoxicity against human HepG2 cells assessed as decrease in cell viability by MTT assay
    		[PMID: 29489361]
    HepG2 IC50
    0.24 μM
    Compound: adriamycin
    Cytotoxic activity against human HepG2 cells by MTT method
    Cytotoxic activity against human HepG2 cells by MTT method
    		[PMID: 25739048]
    HepG2 IC50
    0.25 μM
    Compound: ADR
    Antiproliferative activity against human HepG2 cells incubated for 72 hrs by SRB method
    Antiproliferative activity against human HepG2 cells incubated for 72 hrs by SRB method
    		[PMID: 39054645]
    HepG2 IC50
    0.3 μM
    Compound: DOX.HCl
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 28445049]
    HepG2 IC50
    0.38 μM
    Compound: Adriamycin
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
    		[PMID: 35121401]
    HepG2 IC50
    0.4 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 34176266]
    HepG2 IC50
    0.45 nM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 35152092]
    HepG2 IC50
    0.66 μM
    Compound: Adriamycin
    Anticancer activity against human HepG2 cells assessed as inhibition of cell proliferation
    Anticancer activity against human HepG2 cells assessed as inhibition of cell proliferation
    		[PMID: 32527548]
    HepG2 IC50
    0.66 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 33689875]
    HepG2 IC50
    0.67 μM
    Compound: ADM
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 28818459]
    HepG2 IC50
    0.8 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 34081476]
    HepG2 IC50
    0.8 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 37947788]
    HepG2 IC50
    0.85 μM
    Compound: ADR
    Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay
    		[PMID: 30837097]
    HepG2 IC50
    1 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 20627721]
    HepG2 IC50
    1.09 μM
    Compound: Dox
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 22318158]
    HepG2 IC50
    1.11 μM
    Compound: Doxorubicin.HCl
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 23131338]
    HepG2 IC50
    1.2 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    		[PMID: 32293887]
    HepG2 IC50
    1.3 μM
    Compound: ADM
    Cytotoxicity against human Hep G2 cells
    Cytotoxicity against human Hep G2 cells
    		[PMID: 17067155]
    HepG2 IC50
    1.5 μM
    Compound: Adriamycin
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31268321]
    HepG2 IC50
    1.6 μM
    Compound: ADR
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 33097300]
    HepG2 IC50
    1.9 μM
    Compound: Adriamycin
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31117521]
    HepG2 IC50
    10.1 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 25304898]
    HepG2 IC50
    2.08 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
    		[PMID: 21144747]
    HepG2 IC50
    2.21 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells assessed as inhibition of proliferation incubated for 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as inhibition of proliferation incubated for 72 hrs by MTT assay
    		[PMID: 34237623]
    HepG2 IC50
    2.32 μM
    Compound: ADM
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 30739827]
    HepG2 IC50
    2.5 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 26810315]
    HepG2 IC50
    2.6 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31013087]
    HepG2 IC50
    3.1 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition
    		[PMID: 38862138]
    HepG2 IC50
    3.43 μM
    Compound: DOX
    Anticancer activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Anticancer activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 38389893]
    HepG2 IC50
    < 0.068 mg/mL
    Compound: Doxorubicin
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
    		[PMID: 22142614]
    HepG2 IC50
    < 1 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    		[PMID: 28757067]
    HepG2 IC50
    < 1 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 31804070]
    HepG2 IC50
    < 1.3 μM
    Compound: Adriamycin
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    		[PMID: 21875764]
    HepG2/Adm IC50
    144.35 μM
    Compound: ADM
    Cytotoxicity against human HepG2/ADM cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human HepG2/ADM cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 28818459]
    Hs-578T GI50
    0.596 μg/mL
    Compound: ADR
    Antitumor activity against human Hs 578T cells
    Antitumor activity against human Hs 578T cells
    		[PMID: 20045644]
    Huh-7 IC50
    14.8 μM
    Compound: Adriamycin
    Cytotoxicity against human HuH7 cells by CCK-8 assay
    Cytotoxicity against human HuH7 cells by CCK-8 assay
    		[PMID: 27704808]
    IMR-32 IC50
    0.02 μM
    Compound: Adriamycin
    Cytotoxicity against Homo sapiens (human) IMR32 cells by SRB assay
    Cytotoxicity against Homo sapiens (human) IMR32 cells by SRB assay
    		10.1007/s00044-010-9500-5
    IMR-32 IC50
    1.7 μM
    Compound: Adriamycin
    Cytotoxicity against human IMR-32 cells assessed as inhibition of cell growth incubated for 30 mins by SRB assay
    Cytotoxicity against human IMR-32 cells assessed as inhibition of cell growth incubated for 30 mins by SRB assay
    		[PMID: 30114660]
    K562 GI50
    0.02 μM
    Compound: Doxorubicin hydrochloride
    Growth inhibition of human K562 cells measured after 3 days by trypan blue assay
    Growth inhibition of human K562 cells measured after 3 days by trypan blue assay
    		[PMID: 29565129]
    K562 GI50
    0.17 μM
    Compound: DOX HCl
    Growth inhibition against human K562 cells after 72 hrs by inverted microscopy
    Growth inhibition against human K562 cells after 72 hrs by inverted microscopy
    		[PMID: 23353738]
    K562 GI50
    0.375 μg/mL
    Compound: ADR
    Antitumor activity against human K562 cells
    Antitumor activity against human K562 cells
    		[PMID: 20045644]
    K562 IC50
    0.001 μM
    Compound: ADR
    Cytotoxicity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
    Cytotoxicity against human K562 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
    		[PMID: 36708676]
    K562 IC50
    0.01 μM
    Compound: Adriamycin
    Antiproliferative activity against human K562 cells after 48 hrs by Alamar blue dye based neubauer hemocytometer method
    Antiproliferative activity against human K562 cells after 48 hrs by Alamar blue dye based neubauer hemocytometer method
    		[PMID: 28045256]
    K562 IC50
    0.01 μM
    Compound: Adriamycine
    Antiproliferative activity against human K562 cells after 48 hrs
    Antiproliferative activity against human K562 cells after 48 hrs
    		[PMID: 20537765]
    K562 IC50
    0.01 μM
    Compound: Adriamycine
    Cell growth inhibition of human K562 cells after 48 hrs
    Cell growth inhibition of human K562 cells after 48 hrs
    		[PMID: 20546980]
    K562 IC50
    0.01 μM
    Compound: adriamycin
    Antiproliferative activity against human K562 cells after 48 hrs
    Antiproliferative activity against human K562 cells after 48 hrs
    		[PMID: 17973361]
    K562 IC50
    0.059 μM
    Compound: ADR
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 26832219]
    K562 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 32880456]
    K562 IC50
    0.22 μM
    Compound: Adriamycin
    Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay
    		[PMID: 27503681]
    K562 IC50
    0.25 μM
    Compound: Adriamycin
    Cytotoxicity against human K562 cells by MTT assay
    Cytotoxicity against human K562 cells by MTT assay
    		[PMID: 38662578]
    K562 IC50
    0.3 μM
    Compound: ADM
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 29985604]
    K562 IC50
    0.3 μM
    Compound: ADM
    Cytotoxicity against human K562 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human K562 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 35993848]
    K562 IC50
    0.3 μM
    Compound: Adriamycin
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 28418245]
    K562 IC50
    0.3 μM
    Compound: Adriamycin
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 31904949]
    K562 IC50
    0.3 μM
    Compound: Adriamycin
    Cytotoxicity against human K562 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human K562 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 32840364]
    K562 IC50
    0.3 μM
    Compound: Dox
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 26506221]
    K562 IC50
    0.3 μM
    Compound: adriamycin
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 23806071]
    K562 IC50
    0.34 μM
    Compound: Adriamycin
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth
    Antiproliferative activity against human K562 cells assessed as inhibition of cell growth
    		[PMID: 35931243]
    K562 IC50
    0.36 μM
    Compound: ADM
    Cytotoxicity against human K562 cells after 2 days by MTT assay
    Cytotoxicity against human K562 cells after 2 days by MTT assay
    		[PMID: 21821321]
    K562 IC50
    0.39 μM
    Compound: ADR
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 29335204]
    K562 IC50
    0.43 μM
    Compound: ADR
    Antiproliferative activity against human K562 cells after 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human K562 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 20353152]
    K562 IC50
    0.46 μM
    Compound: ADR
    Cytotoxicity against human K562 cells assessed as decrease in cell survival rate incubated for 72 hrs by MTS assay
    Cytotoxicity against human K562 cells assessed as decrease in cell survival rate incubated for 72 hrs by MTS assay
    		[PMID: 36780419]
    K562 IC50
    0.47 μM
    Compound: Adriamycin
    Cytotoxicity against human K562 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 27318123]
    K562 IC50
    0.51 μM
    Compound: ADM
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 28301155]
    K562 IC50
    0.57 μM
    Compound: Adriamycin
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 28222318]
    K562 IC50
    0.59 μM
    Compound: ADR
    Anti-proliferative activity against human K562 cells measured after 72 hrs by MTS assay
    Anti-proliferative activity against human K562 cells measured after 72 hrs by MTS assay
    		[PMID: 28068095]
    K562 IC50
    0.61 μM
    Compound: ADR
    Antiproliferative activity in human K562 cells after 48 hrs by MTT assay
    Antiproliferative activity in human K562 cells after 48 hrs by MTT assay
    		[PMID: 28570977]
    K562 IC50
    0.63 μM
    Compound: ADM
    Cytotoxicity against human K562 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    		[PMID: 30827866]
    K562 IC50
    0.74 μM
    Compound: ADR
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human K562 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 33097300]
    K562 IC50
    0.83 μM
    Compound: ADR
    Antiproliferative activity against human K562 cells by MTT assay
    Antiproliferative activity against human K562 cells by MTT assay
    		[PMID: 33132117]
    K562 IC50
    0.92 μM
    Compound: ADM
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 35247755]
    K562 IC50
    0.97 μM
    Compound: ADM
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 29631786]
    K562 IC50
    1.2 μM
    Compound: doxorubicin hydrochloride
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 19256529]
    K562 IC50
    108.4 nM
    Compound: Adriamycin
    Antiproliferative activity against human K562 cells measured after 72 hrs by SRB assay
    Antiproliferative activity against human K562 cells measured after 72 hrs by SRB assay
    		[PMID: 34794817]
    K562 IC50
    2.35 μM
    Compound: Dox
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 22318158]
    K562 IC50
    2.45 μM
    Compound: Adriamycin
    Cytotoxicity against human K562 cells in presence of 10% fetal bovine serum
    Cytotoxicity against human K562 cells in presence of 10% fetal bovine serum
    		[PMID: 20188578]
    K562 IC50
    2.5 μM
    Compound: Adriamycin
    Cytotoxicity against human K562 cells after 4 days by ELISA reader assay
    Cytotoxicity against human K562 cells after 4 days by ELISA reader assay
    		[PMID: 19939682]
    K562 IC50
    4.29 μM
    Compound: ADM
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells after 48 hrs by MTT assay
    		[PMID: 28645831]
    K562 IC50
    6.23 μM
    Compound: ADM
    Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 27073052]
    K562 IC50
    77.7 nM
    Compound: ADR
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
    		[PMID: 28333459]
    K562 IC50
    77.7 nM
    Compound: ADR
    Antiproliferative activity against human K562 cells
    Antiproliferative activity against human K562 cells
    		[PMID: 31171403]
    K562 IC50
    8.9 μM
    Compound: Adriamycin
    Cytotoxicity against human K562 cells by MTT assay
    Cytotoxicity against human K562 cells by MTT assay
    		[PMID: 25304898]
    K562/A02 IC50
    10.55 μM
    Compound: ADR
    Cytotoxicity against human K562/A02 cells after 72 hrs by MTT assay
    Cytotoxicity against human K562/A02 cells after 72 hrs by MTT assay
    		[PMID: 26832219]
    K562/A02 IC50
    19.21 μM
    Compound: ADM
    Cytotoxicity against human K562/A02 cells after 2 days by MTT assay
    Cytotoxicity against human K562/A02 cells after 2 days by MTT assay
    		[PMID: 21821321]
    K562/A02 IC50
    2.4 μM
    Compound: ADR
    Cytotoxicity against human K562/A02 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
    Cytotoxicity against human K562/A02 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
    		[PMID: 36708676]
    K562/A02 IC50
    23.42 μM
    Compound: ADR
    Antiproliferative activity against human K562/A02 cells overexpressing P-gp by MTT assay
    Antiproliferative activity against human K562/A02 cells overexpressing P-gp by MTT assay
    		[PMID: 33132117]
    K562/A02 IC50
    23.81 μM
    Compound: ADR
    Antiproliferative activity against human K562/A02 cells after 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human K562/A02 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 20353152]
    K562/A02 IC50
    24.46 μM
    Compound: ADR
    Anti-proliferative activity against P-gp overexpressing/drug resistant human K562/A02 cells measured after 72 hrs by MTS assay
    Anti-proliferative activity against P-gp overexpressing/drug resistant human K562/A02 cells measured after 72 hrs by MTS assay
    		[PMID: 28068095]
    K562/A02 IC50
    25.04 μM
    Compound: ADR
    Cytotoxicity against human K562/A02 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    Cytotoxicity against human K562/A02 cells assessed as reduction in cell viability after 72 hrs by MTS assay
    		[PMID: 29335204]
    K562/A02 IC50
    38.02 μM
    Compound: ADM
    Cytotoxicity against human K562/A02 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human K562/A02 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 27073052]
    K562/A02 IC50
    53.95 μM
    Compound: ADM
    Cytotoxicity against human K562/A02 cells overexpressing P-gp after 48 hrs by MTT assay
    Cytotoxicity against human K562/A02 cells overexpressing P-gp after 48 hrs by MTT assay
    		[PMID: 28301155]
    K562/A02 IC50
    54.22 μM
    Compound: ADM
    Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay
    Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay
    		[PMID: 25464884]
    K562/A02 IC50
    58.6 μM
    Compound: ADR
    Cytotoxicity against human K562/A02 cells overexpressing ABCB1 assessed as decrease in cell survival rate incubated for 72 hrs by MTS assay
    Cytotoxicity against human K562/A02 cells overexpressing ABCB1 assessed as decrease in cell survival rate incubated for 72 hrs by MTS assay
    		[PMID: 36780419]
    K562/A02 IC50
    65.57 μM
    Compound: ADM
    Cytotoxicity against human K562/A02 cells overexpressing P-gp assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human K562/A02 cells overexpressing P-gp assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 29631786]
    K562/A02 IC50
    78.34 μM
    Compound: ADM
    Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay
    Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay
    		[PMID: 35247755]
    K562/A02 IC50
    96.91 μM
    Compound: ADM
    Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay
    Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay
    		[PMID: 28645831]
    K562/Adr IC50
    18.779 μM
    Compound: Adriamycin
    Antiproliferative activity against human K562/ADR cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human K562/ADR cells after 72 hrs by CCK8 assay
    		[PMID: 27503681]
    K562/Adr IC50
    31191 nM
    Compound: Adriamycin
    Antiproliferative activity against human K562/Adr cells measured after 72 hrs by SRB assay
    Antiproliferative activity against human K562/Adr cells measured after 72 hrs by SRB assay
    		[PMID: 34794817]
    K562/Adr IC50
    3310.2 nM
    Compound: ADR
    Antiproliferative activity against human K562/ADR cells after 72 hrs by MTT assay
    Antiproliferative activity against human K562/ADR cells after 72 hrs by MTT assay
    		[PMID: 28333459]
    K562/Adr IC50
    3310.2 nM
    Compound: ADR
    Antiproliferative activity against drug- resistant human K562/ADR cells
    Antiproliferative activity against drug- resistant human K562/ADR cells
    		[PMID: 31171403]
    KB GI50
    0.13 μM
    Compound: ADR
    Cytotoxicity against human KB cells after 48 hrs by SRB assay
    Cytotoxicity against human KB cells after 48 hrs by SRB assay
    		[PMID: 20554354]
    KB GI50
    0.13 μM
    Compound: ADR
    Cytotoxicity against human KB cells after 48 hrs by sulforhodamine B based ELISA
    Cytotoxicity against human KB cells after 48 hrs by sulforhodamine B based ELISA
    		[PMID: 21402478]
    KB GI50
    0.16 μM
    Compound: ADR
    Anticancer activity against human KB cells after 48 hrs by SRB assay
    Anticancer activity against human KB cells after 48 hrs by SRB assay
    		[PMID: 20557981]
    KB GI50
    0.17 μM
    Compound: ADR
    Cytotoxicity against human KB cells after 48 hrs by SRB assay
    Cytotoxicity against human KB cells after 48 hrs by SRB assay
    		[PMID: 20444601]
    KB GI50
    0.17 μM
    Compound: ADR
    Cytotoxicity against human KB cells by sulforhodamine B method
    Cytotoxicity against human KB cells by sulforhodamine B method
    		[PMID: 21459581]
    KB GI50
    0.19 μM
    Compound: ADR
    Cytotoxicity against human KB cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human KB cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21194809]
    KB IC50
    0.01 μM
    Compound: Doxorubicin.HCl
    Cytotoxicity against human KB cells after 48 hrs by MTT assay
    Cytotoxicity against human KB cells after 48 hrs by MTT assay
    		[PMID: 23131338]
    KB IC50
    0.27 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human KB cells after 45 hrs by resazurin microplate assay
    Cytotoxicity against human KB cells after 45 hrs by resazurin microplate assay
    		[PMID: 21473608]
    KB IC50
    0.28 μM
    Compound: doxorubicin hydrochloride
    Cytotoxicity against human KB cells after 45 hrs by resazurin microplate assay
    Cytotoxicity against human KB cells after 45 hrs by resazurin microplate assay
    		[PMID: 20364867]
    KB IC50
    0.57 μM
    Compound: Adr
    Cytotoxicity against human KB cells by SRB assay
    Cytotoxicity against human KB cells by SRB assay
    		[PMID: 29182349]
    KB IC50
    0.6 μM
    Compound: Adriamycin
    Cytotoxicity against human KB cells by MTT assay
    Cytotoxicity against human KB cells by MTT assay
    		[PMID: 20627721]
    KB IC50
    0.6 μM
    Compound: Adriamycin
    Cytotoxicity against human KB cells by MTT assay
    Cytotoxicity against human KB cells by MTT assay
    		[PMID: 21875764]
    KB IC50
    0.84 μM
    Compound: DOX
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    Cytotoxicity against human KB cells after 72 hrs by SRB assay
    		[PMID: 22574992]
    KB IC50
    0.84 μM
    Compound: DOX
    Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 24686017]
    KB IC50
    1.2 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human KB cells by resazurin microplate assay
    Cytotoxicity against human KB cells by resazurin microplate assay
    		[PMID: 21995505]
    KB IC50
    1.66 μg/mL
    Compound: ADR
    Cytotoxicity against human KB cells after 48 hrs by MTT assay
    Cytotoxicity against human KB cells after 48 hrs by MTT assay
    		[PMID: 20724170]
    KB IC50
    10 μg/mL
    Compound: adriamycin
    Cytotoxicity against human KB cells by MTT assay
    Cytotoxicity against human KB cells by MTT assay
    		[PMID: 17512094]
    KB IC50
    2.2 μM
    Compound: Adriamycin
    Cytotoxicity against human KB cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human KB cells incubated for 48 hrs by MTT assay
    		[PMID: 32394716]
    KB IC50
    3.2 μM
    Compound: Adriamycin
    Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31268321]
    KB-V1 IC50
    1.02 μM
    Compound: 1
    Cytotoxicity against human vinblastine-resistant KBV1 cells after 72 hrs by MTT assay in presence of 24 mM ABC transporter inhibitor verapamil hydrochloride
    Cytotoxicity against human vinblastine-resistant KBV1 cells after 72 hrs by MTT assay in presence of 24 mM ABC transporter inhibitor verapamil hydrochloride
    		[PMID: 20133021]
    KB-V1 IC50
    18.3 μM
    Compound: 1
    Cytotoxicity against human vinblastine-resistant KBV1 cells after 72 hrs by MTT assay
    Cytotoxicity against human vinblastine-resistant KBV1 cells after 72 hrs by MTT assay
    		[PMID: 20133021]
    KB-V1 IC50
    35.6 μM
    Compound: 1
    Cytotoxicity against human vinblastine-resistant KBV1 cells after 48 hrs by MTT assay
    Cytotoxicity against human vinblastine-resistant KBV1 cells after 48 hrs by MTT assay
    		[PMID: 20133021]
    KB-V1 IC50
    59.9 μM
    Compound: 1
    Cytotoxicity against human vinblastine-resistant KBV1 cells after 24 hrs by MTT assay
    Cytotoxicity against human vinblastine-resistant KBV1 cells after 24 hrs by MTT assay
    		[PMID: 20133021]
    KG-1a IC50
    0.08 μM
    Compound: ADR
    Cytotoxicity against human KG1a cells assessed as decrease in cell proliferation after 48 hrs by MTT assay
    Cytotoxicity against human KG1a cells assessed as decrease in cell proliferation after 48 hrs by MTT assay
    		[PMID: 28068601]
    KG-1a IC50
    0.82 μM
    Compound: ADR
    Cytotoxicity against human KG1a cells after 72 hrs by MTT assay
    Cytotoxicity against human KG1a cells after 72 hrs by MTT assay
    		[PMID: 26832219]
    L02 IC50
    0.2 μM
    Compound: ADM
    Cytotoxicity against human L02 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human L02 cells assessed as reduction in cell viability by SRB assay
    		[PMID: 35993848]
    L02 IC50
    0.5 μM
    Compound: Adriamycin
    Cytotoxicity against human L02 cells after 24 hrs by SRB method
    Cytotoxicity against human L02 cells after 24 hrs by SRB method
    		[PMID: 31904949]
    L02 IC50
    0.7 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human L02 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human L02 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 34176266]
    L02 IC50
    0.79 μM
    Compound: ADR
    Cytotoxicity against human L02 cells measured after 48 hrs by MTT assay
    Cytotoxicity against human L02 cells measured after 48 hrs by MTT assay
    		[PMID: 30837097]
    L02 IC50
    13.5 μM
    Compound: Adriamycin
    Cytotoxicity against human LO2 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human LO2 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31013087]
    L02 IC50
    23.54 μM
    Compound: DOX
    Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 38389893]
    L1210 ED50
    0.016 μg/mL
    Compound: Adriamycin
    Anticancer activity against mouse L1210 cells
    Anticancer activity against mouse L1210 cells
    		[PMID: 35367708]
    L1210 ED50
    0.07 μg/mL
    Compound: Adriamycin
    Anticancer activity against mouse L1210 cells assessed as reduction in cell viability for 72 hrs by MTT assay
    Anticancer activity against mouse L1210 cells assessed as reduction in cell viability for 72 hrs by MTT assay
    		[PMID: 35367708]
    L1210 ED50
    0.1 μM
    Compound: Doxorubicin
    In vitro cytotoxicity against Leukemia L1210 cell line
    In vitro cytotoxicity against Leukemia L1210 cell line
    		[PMID: 15982876]
    L1210 ED50
    0.58 μM
    Compound: 2 (Doxorubicin hydrochloride)
    Inhibition of [3H]uridine incorporation into proliferating L1210 cells.
    Inhibition of [3H]uridine incorporation into proliferating L1210 cells.
    		[PMID: 6716401]
    L1210 ED50
    0.67 μM
    Compound: 2
    Inhibition of RNA synthesis in mouse L1210 cells
    Inhibition of RNA synthesis in mouse L1210 cells
    		[PMID: 690999]
    L1210 ED50
    0.7 μM
    Compound: 1
    Dose required to inhibit the RNA synthesis in leukemia L1210 cells
    Dose required to inhibit the RNA synthesis in leukemia L1210 cells
    		[PMID: 7252976]
    L1210 ED50
    1.5 μM
    Compound: 1
    Dose required to inhibit the DNA synthesis in leukemia L1210 cells
    Dose required to inhibit the DNA synthesis in leukemia L1210 cells
    		[PMID: 7252976]
    L1210 ED50
    1.5 μM
    Compound: 2
    Inhibition of DNA synthesis in mouse L1210 cells
    Inhibition of DNA synthesis in mouse L1210 cells
    		[PMID: 690999]
    L1210 ED50
    1.6 μM
    Compound: 2 (Doxorubicin hydrochloride)
    Inhibition of [3H]thymidine incorporation into proliferating L1210 cells.
    Inhibition of [3H]thymidine incorporation into proliferating L1210 cells.
    		[PMID: 6716401]
    L929 IC50
    2.04 μM
    Compound: 11
    Cytotoxicity against mouse L929 cells incubated for 72 hrs by MTT assay
    Cytotoxicity against mouse L929 cells incubated for 72 hrs by MTT assay
    		[PMID: 37593579]
    L929 IC50
    7.5 μM
    Compound: Doxorubicin HCl
    Antiproliferative activity against mouse L929 cells after 72 hrs by MTT assay
    Antiproliferative activity against mouse L929 cells after 72 hrs by MTT assay
    		[PMID: 29884536]
    LoVo GI50
    0.24 μM
    Compound: DOX HCl
    Growth inhibition against human LoVo cells after 72 hrs by inverted microscopy
    Growth inhibition against human LoVo cells after 72 hrs by inverted microscopy
    		[PMID: 23353738]
    LoVo IC50
    0.11 μM
    Compound: DOX
    Cytotoxicity against human LoVo cells after 72 hrs by SRB assay
    Cytotoxicity against human LoVo cells after 72 hrs by SRB assay
    		[PMID: 22574992]
    LoVo IC50
    0.11 μM
    Compound: DOX
    Cytotoxicity against human LoVo cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against human LoVo cells assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 24686017]
    LoVo IC50
    0.2 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
    Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
    		[PMID: 15387667]
    LoVo IC50
    13.2 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human doxorubicin-resistant LoVo cells after 72 hrs by MTT assay
    Cytotoxicity against human doxorubicin-resistant LoVo cells after 72 hrs by MTT assay
    		[PMID: 15387667]
    MCF-10A GI50
    0.04 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human MCF10A cells assessed as cell growth inhibition after 48 hrs by SRB assay
    Cytotoxicity against human MCF10A cells assessed as cell growth inhibition after 48 hrs by SRB assay
    		[PMID: 27598688]
    MCF-10A IC50
    0.16 μM
    Compound: ADR
    Antiproliferative activity against human MCF-10A cells incubated for 72 hrs by SRB assay
    Antiproliferative activity against human MCF-10A cells incubated for 72 hrs by SRB assay
    		[PMID: 39054645]
    MCF-10A IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF10A cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF10A cells after 72 hrs by MTT assay
    		[PMID: 29286660]
    MCF-10A IC50
    0.86 μM
    Compound: ADR
    Antiproliferative activity against human MCF-10A cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human MCF-10A cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 34992039]
    MCF-10A IC50
    0.89 μM
    Compound: ADR
    Cytotoxic activity against human MCF-10A assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxic activity against human MCF-10A assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 35390712]
    MCF-10A IC50
    0.93 μM
    Compound: ADM
    Cytotoxicity against human MCF10A cells after 72 hrs by cell counting kit-8 analysis
    Cytotoxicity against human MCF10A cells after 72 hrs by cell counting kit-8 analysis
    		[PMID: 29174815]
    MCF-10A IC50
    1.11 μM
    Compound: Doxorubicin
    Growth inhibition of human MCF10A cells after 72 hrs by CellTiter-Blue assay
    Growth inhibition of human MCF10A cells after 72 hrs by CellTiter-Blue assay
    		[PMID: 24153206]
    MCF7 EC50
    0.7 μM
    Compound: Adriamycin
    Antiproliferative activity against human ER-positive MCF7 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human ER-positive MCF7 cells measured after 48 hrs by MTT assay
    		[PMID: 27344488]
    MCF7 ED50
    3.4 μM
    Compound: Adriamycin
    Cytotoxicity against MCF-7 cell line in the purdue cell culture screen was determined
    Cytotoxicity against MCF-7 cell line in the purdue cell culture screen was determined
    		[PMID: 10091695]
    MCF7 GI50
    0.00018 μM
    Compound: Adriamycin
    Growth inhibition of human MCF7 cells after 48 hrs by SRB assay
    Growth inhibition of human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 31330449]
    MCF7 GI50
    0.054 μM
    Compound: Adr
    Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay
    		[PMID: 26741854]
    MCF7 GI50
    0.054 μM
    Compound: Adr
    Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay
    		[PMID: 29102180]
    MCF7 GI50
    0.13 μM
    Compound: ADR
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B based ELISA
    Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B based ELISA
    		[PMID: 21402478]
    MCF7 GI50
    0.17 mM
    Compound: Adriamycin
    Growth inhibition of human MCF7 cells after 48 hrs by MTT assay
    Growth inhibition of human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 32631569]
    MCF7 GI50
    0.17 μM
    Compound: ADR
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 20444601]
    MCF7 GI50
    0.17 μM
    Compound: ADR
    Cytotoxicity against human MCF7 cells by sulforhodamine B method
    Cytotoxicity against human MCF7 cells by sulforhodamine B method
    		[PMID: 21459581]
    MCF7 GI50
    0.23 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells assessed as growth inhibition by SRB assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition by SRB assay
    		[PMID: 24507920]
    MCF7 GI50
    50.2 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth by SRB assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth by SRB assay
    		[PMID: 32791404]
    MCF7 GI50
    < 0.1 μM
    Compound: ADR
    Growth inhibition of Homo sapiens (human) MCF-7 cells after 48 hr by SRB assay
    Growth inhibition of Homo sapiens (human) MCF-7 cells after 48 hr by SRB assay
    		10.1007/s00044-011-9688-z
    MCF7 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay
    Cytotoxicity against Homo sapiens (human) MCF7 cells after 48 hr by SRB assay
    		10.1007/s00044-012-0423-1
    MCF7 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 20554354]
    MCF7 GI50
    < 0.1 μM
    Compound: ADR
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    		[PMID: 26994845]
    MCF7 GI50
    < 0.1 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
    		[PMID: 28258796]
    MCF7 GI50
    < 10 μg/mL
    Compound: Adriamycin
    Growth inhibition of human MCF7 cells assessed as cell growth inhibition by SRB assay
    Growth inhibition of human MCF7 cells assessed as cell growth inhibition by SRB assay
    		[PMID: 36481599]
    MCF7 IC50
    0.0012 μM
    Compound: Adiramycin
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth by MTT assay
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth by MTT assay
    		[PMID: 33940466]
    MCF7 IC50
    0.075 μM
    Compound: Doxorubicin
    Growth inhibition of human MCF7 cells after 72 hrs by CellTiter-Blue assay
    Growth inhibition of human MCF7 cells after 72 hrs by CellTiter-Blue assay
    		[PMID: 24153206]
    MCF7 IC50
    0.08 μM
    Compound: 1
    Cytotoxicity against human topotecan-resistant MCF7 cells after 72 hrs by MTT assay in presence of 1.2 mM BCRP inhibitor fumitremorgin C
    Cytotoxicity against human topotecan-resistant MCF7 cells after 72 hrs by MTT assay in presence of 1.2 mM BCRP inhibitor fumitremorgin C
    		[PMID: 20133021]
    MCF7 IC50
    0.1 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 29286660]
    MCF7 IC50
    0.144 μM
    Compound: Doxorubicin Hydrochloride
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 37729693]
    MCF7 IC50
    0.15 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay
    		[PMID: 21192108]
    MCF7 IC50
    0.2 μM
    Compound: 11
    Anticancer activity against human MCF7 cells incubated for 72 hrs by MTT assay
    Anticancer activity against human MCF7 cells incubated for 72 hrs by MTT assay
    		[PMID: 37593579]
    MCF7 IC50
    0.2 μM
    Compound: ADM
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 28749671]
    MCF7 IC50
    0.39 μM
    Compound: ADR
    Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by sulforhodamine B assay
    		[PMID: 20353152]
    MCF7 IC50
    0.4 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 30049584]
    MCF7 IC50
    0.42 μM
    Compound: ADR
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 30677614]
    MCF7 IC50
    0.44 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay
    		[PMID: 22574992]
    MCF7 IC50
    0.44 μM
    Compound: DOX
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 24686017]
    MCF7 IC50
    0.65 μM
    Compound: adriamycine
    Cytotoxic activity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxic activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 19618898]
    MCF7 IC50
    0.66 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells assessed as cell viability by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell viability by MTT assay
    		[PMID: 38387332]
    MCF7 IC50
    0.67 μM
    Compound: ADR
    Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay
    		[PMID: 30837097]
    MCF7 IC50
    0.67 μM
    Compound: ADR
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 35339100]
    MCF7 IC50
    0.7 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 29215886]
    MCF7 IC50
    0.72 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay
    		[PMID: 33689875]
    MCF7 IC50
    0.72 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition
    		[PMID: 38862138]
    MCF7 IC50
    0.8 μM
    Compound: Adriamycin
    Cytotoxicity against Homo sapiens (human) MCF7 cells by SRB assay
    Cytotoxicity against Homo sapiens (human) MCF7 cells by SRB assay
    		10.1007/s00044-010-9500-5
    MCF7 IC50
    0.88 μM
    Compound: AMD
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 25408835]
    MCF7 IC50
    0.99 μM
    Compound: Adriamycin
    Cytotoxicity against human wild-type MCF7 cells after 72 hrs
    Cytotoxicity against human wild-type MCF7 cells after 72 hrs
    		[PMID: 28720329]
    MCF7 IC50
    1 μM
    Compound: 1
    Cytotoxicity against human topotecan-resistant MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human topotecan-resistant MCF7 cells after 72 hrs by MTT assay
    		[PMID: 20133021]
    MCF7 IC50
    1 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    		[PMID: 27240278]
    MCF7 IC50
    1 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 30222343]
    MCF7 IC50
    1 μM
    Compound: Adriamycin
    Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31268321]
    MCF7 IC50
    1 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 37947788]
    MCF7 IC50
    1.02 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 34081476]
    MCF7 IC50
    1.1 μM
    Compound: ADR
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 33097300]
    MCF7 IC50
    1.13 μM
    Compound: ADR
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 35390712]
    MCF7 IC50
    1.2 μM
    Compound: 4; ADR
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 28803046]
    MCF7 IC50
    1.2 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 34176266]
    MCF7 IC50
    1.3 μM
    Compound: 1
    Cytotoxicity against human topotecan-resistant MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human topotecan-resistant MCF7 cells after 48 hrs by MTT assay
    		[PMID: 20133021]
    MCF7 IC50
    1.3 μM
    Compound: Adriamycin
    Cytotoxicity against vinblastine-sensitive human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against vinblastine-sensitive human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 28006904]
    MCF7 IC50
    1.31 μM
    Compound: ADR
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 34992039]
    MCF7 IC50
    1.5 μM
    Compound: doxorubicin hydrochloride
    Cytotoxicity against human MCF7 cells after 45 hrs by resazurin microplate assay
    Cytotoxicity against human MCF7 cells after 45 hrs by resazurin microplate assay
    		[PMID: 20364867]
    MCF7 IC50
    1.65 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 21123066]
    MCF7 IC50
    1.72 μM
    Compound: Adriamycin
    Growth inhibition of human MCF7 cells after 48 hrs by MTT assay
    Growth inhibition of human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 29903663]
    MCF7 IC50
    15 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human MCF7 cells by resazurin microplate assay
    Cytotoxicity against human MCF7 cells by resazurin microplate assay
    		[PMID: 21995505]
    MCF7 IC50
    15.8 μM
    Compound: Adriamycin
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay
    		[PMID: 34648295]
    MCF7 IC50
    18.14 μM
    Compound: Adriamycin
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 37856840]
    MCF7 IC50
    18.9 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 4 days by MTT assay
    Cytotoxicity against human MCF7 cells after 4 days by MTT assay
    		[PMID: 20619511]
    MCF7 IC50
    2.1 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 4 days by ELISA reader assay
    Cytotoxicity against human MCF7 cells after 4 days by ELISA reader assay
    		[PMID: 19939682]
    MCF7 IC50
    2.3 μM
    Compound: ADR
    Antiproliferative activity in human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity in human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 28570977]
    MCF7 IC50
    2.5 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells incubated for 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells incubated for 48 hrs by MTT assay
    		[PMID: 32394716]
    MCF7 IC50
    2.78 μM
    Compound: Doxorubicin.HCl
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 25529734]
    MCF7 IC50
    22.2 nM
    Compound: Adriamycin
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 27213819]
    MCF7 IC50
    25.6 nM
    Compound: Adriamycin
    Cytotoxicity in human MCF7 assessed as inhibition in cell growth measured after 24 hrs by MTT assay
    Cytotoxicity in human MCF7 assessed as inhibition in cell growth measured after 24 hrs by MTT assay
    		[PMID: 35084853]
    MCF7 IC50
    25.9 μM
    Compound: Adriamycin
    Antiproliferative activity against human MCF7 cells by SRB assay
    Antiproliferative activity against human MCF7 cells by SRB assay
    		[PMID: 32688198]
    MCF7 IC50
    27.92 μM
    Compound: ADR
    Antiproliferative activity against human MCF7/ADR cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7/ADR cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 34992039]
    MCF7 IC50
    28.4 μM
    Compound: ADR
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 34649064]
    MCF7 IC50
    28.8 nM
    Compound: Adriamycin
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs
    		[PMID: 38430854]
    MCF7 IC50
    3.2 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF-7 cells assessed as cell viability inhibition for 48 hrs by MTT assay
    Cytotoxicity against human MCF-7 cells assessed as cell viability inhibition for 48 hrs by MTT assay
    		[PMID: 33913326]
    MCF7 IC50
    3.23 ng/mL
    Compound: 2b
    Concentration required to inhibit proliferation of human mammary adenocarcinoma MCF-7 cell line was determined using MTT assay
    Concentration required to inhibit proliferation of human mammary adenocarcinoma MCF-7 cell line was determined using MTT assay
    		[PMID: 15324908]
    MCF7 IC50
    4.6 μM
    Compound: Doxorubicin HCl
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
    		[PMID: 29884536]
    MCF7 IC50
    4.9 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human MCF7 cells after 45 hrs by resazurin microplate assay
    Cytotoxicity against human MCF7 cells after 45 hrs by resazurin microplate assay
    		[PMID: 21473608]
    MCF7 IC50
    44.8 nM
    Compound: Adriamycin
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 28763646]
    MCF7 IC50
    44.82 nM
    Compound: Adriamycin
    Antiproliferative activity against human MCF7 cells after 48 to 72 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 48 to 72 hrs by MTT assay
    		[PMID: 29754076]
    MCF7 IC50
    5.1 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 20627721]
    MCF7 IC50
    5.1 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells by MTT assay
    Cytotoxicity against human MCF7 cells by MTT assay
    		[PMID: 21875764]
    MCF7 IC50
    5.3 μM
    Compound: Adriamycin
    Cytotoxicity against multidrug resistant human MCF7 cells cultured in vinblastine containing medium assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against multidrug resistant human MCF7 cells cultured in vinblastine containing medium assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 28006904]
    MCF7 IC50
    5.31 μM
    Compound: Adriamycin
    Antiproliferative activity against human MCF7 cells measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human MCF7 cells measured after 72 hrs by CCK8 assay
    		[PMID: 27654394]
    MCF7 IC50
    5.75 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells after 3 days
    Cytotoxicity against human MCF7 cells after 3 days
    		[PMID: 19954977]
    MCF7 IC50
    6.2 μM
    Compound: 1
    Cytotoxicity against human topotecan-resistant MCF7 cells after 24 hrs by MTT assay
    Cytotoxicity against human topotecan-resistant MCF7 cells after 24 hrs by MTT assay
    		[PMID: 20133021]
    MCF7 IC50
    6.85 x 10-5 μM
    Compound: Adiramycin
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth
    Anticancer activity against human MCF7 cells assessed as inhibition of cell growth
    		[PMID: 33940466]
    MCF7 IC50
    9.2 μM
    Compound: Adriamycin
    Cytotoxicity against multidrug resistant human MCF7 cells cultured in vinblastine free medium assessed as growth inhibition after 72 hrs by SRB assay
    Cytotoxicity against multidrug resistant human MCF7 cells cultured in vinblastine free medium assessed as growth inhibition after 72 hrs by SRB assay
    		[PMID: 28006904]
    MCF7 IC50
    94.1 μM
    Compound: AMD
    Cytotoxicity against adriamycin-resistant human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against adriamycin-resistant human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 25408835]
    MCF7 IC50
    < 0.068 mg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 22142614]
    MCF7 IC50
    < 0.1 μM
    Compound: Adiramycin
    Cytotoxicity against human MCF7 cells by SRB method
    Cytotoxicity against human MCF7 cells by SRB method
    		[PMID: 24951333]
    MCF7 IC50
    < 1 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    		[PMID: 28757067]
    MCF7 IC50
    < 1 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 31804070]
    MCF7 IC50
    < 10 μM
    Compound: Adriamycin
    Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 35694689]
    MCF7 IC50
    > 10 μM
    Compound: adriamicin
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		[PMID: 21090801]
    MCF7R ED50
    0.6 μM
    Compound: Adriamycin
    Cytotoxicity against MCF-7R cell line in the purdue cell culture screen was determined
    Cytotoxicity against MCF-7R cell line in the purdue cell culture screen was determined
    		[PMID: 10091695]
    MDA-MB-231 EC50
    2.3 μM
    Compound: Adriamycin
    Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay
    		[PMID: 27344488]
    MDA-MB-231 GI50
    0.07 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay
    		[PMID: 29878761]
    MDA-MB-231 GI50
    0.08 μM
    Compound: Adriamycin
    Growth inhibition of human MDA-MB-231 cells by SRB assay
    Growth inhibition of human MDA-MB-231 cells by SRB assay
    		[PMID: 36040099]
    MDA-MB-231 GI50
    0.09 μM
    Compound: doxorubicin hydrochloride
    Antitumor activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    Antitumor activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    		[PMID: 21718029]
    MDA-MB-231 GI50
    0.12 μM
    Compound: Adr
    Antiproliferative activity against human MDA-MB-231 cells after 96 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 96 hrs by MTT assay
    		[PMID: 29102180]
    MDA-MB-231 GI50
    0.15 μM
    Compound: ADR
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 31668073]
    MDA-MB-231 IC50
    0.096 μM
    Compound: Doxorubicin Hydrochloride
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
    		[PMID: 37729693]
    MDA-MB-231 IC50
    0.15 μM
    Compound: ADR
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method
    		[PMID: 35302779]
    MDA-MB-231 IC50
    0.18 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells by SRB assay
    Cytotoxicity against human MDA-MB-231 cells by SRB assay
    		[PMID: 38662578]
    MDA-MB-231 IC50
    0.19 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33774342]
    MDA-MB-231 IC50
    0.2 μM
    Compound: ADM
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    		[PMID: 35380848]
    MDA-MB-231 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 34282909]
    MDA-MB-231 IC50
    0.23 μM
    Compound: ADR
    Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay
    		[PMID: 39054645]
    MDA-MB-231 IC50
    0.3 μM
    Compound: ADM
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability by SRB assay
    		[PMID: 35993848]
    MDA-MB-231 IC50
    0.3 μM
    Compound: Adriamycin
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    		[PMID: 31397570]
    MDA-MB-231 IC50
    0.37 μM
    Compound: Adriamycin
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CCK-8 assay
    		[PMID: 35121401]
    MDA-MB-231 IC50
    0.39 μM
    Compound: Doxorubicin
    Growth inhibition of human MDA-MB-231 cells after 72 hrs by CellTiter-Blue assay
    Growth inhibition of human MDA-MB-231 cells after 72 hrs by CellTiter-Blue assay
    		[PMID: 24153206]
    MDA-MB-231 IC50
    0.4 μM
    Compound: ADR
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 35762988]
    MDA-MB-231 IC50
    0.4 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells after 2 days by automatic ELISA reader system
    Cytotoxicity against human MDA-MB-231 cells after 2 days by automatic ELISA reader system
    		[PMID: 20392646]
    MDA-MB-231 IC50
    0.5 μM
    Compound: ADR
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 38253024]
    MDA-MB-231 IC50
    0.54 μM
    Compound: Doxorubicin.HCl
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 30223117]
    MDA-MB-231 IC50
    0.6 μM
    Compound: Adriamycin
    Anti-proliferative activity against human MDA-MB-231 cells by XTT assay
    Anti-proliferative activity against human MDA-MB-231 cells by XTT assay
    		[PMID: 25442319]
    MDA-MB-231 IC50
    0.8 μM
    Compound: ADR
    Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by MTT assay
    		[PMID: 30739826]
    MDA-MB-231 IC50
    0.82 μM
    Compound: ADR
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 34992039]
    MDA-MB-231 IC50
    0.84 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells after 2 days
    Cytotoxicity against human MDA-MB-231 cells after 2 days
    		[PMID: 21419530]
    MDA-MB-231 IC50
    0.84 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells assessed as cell viability by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as cell viability by MTT assay
    		[PMID: 38387332]
    MDA-MB-231 IC50
    0.86 μM
    Compound: ADR
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 35390712]
    MDA-MB-231 IC50
    1.01 μM
    Compound: Adriamycin
    Antiproliferative activity against human MDA-MB-231 cells assessed as suppression of cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as suppression of cell growth incubated for 72 hrs by SRB assay
    		[PMID: 36764122]
    MDA-MB-231 IC50
    1.16 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells after 3 days
    Cytotoxicity against human MDA-MB-231 cells after 3 days
    		[PMID: 19954977]
    MDA-MB-231 IC50
    1.2 μM
    Compound: DOX.HCl
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 28445049]
    MDA-MB-231 IC50
    1.45 μM
    Compound: Dox
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 22318158]
    MDA-MB-231 IC50
    1.67 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    Cytotoxicity against human MDA-MB-231 cells by MTT assay
    		[PMID: 19836231]
    MDA-MB-231 IC50
    1.8 μM
    Compound: 4; ADR
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 48 hrs by MTT assay
    		[PMID: 28803046]
    MDA-MB-231 IC50
    2.19 μM
    Compound: Adriamycin
    Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay
    Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 29903663]
    MDA-MB-231 IC50
    2.26 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 21144747]
    MDA-MB-231 IC50
    2.94 μM
    Compound: ADR
    Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay
    		[PMID: 30837097]
    MDA-MB-231 IC50
    3 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    		[PMID: 29286660]
    MDA-MB-231 IC50
    3.15 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 20093033]
    MDA-MB-231 IC50
    3.6 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay
    Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay
    		[PMID: 27707625]
    MDA-MB-231 IC50
    4.06 μM
    Compound: Doxorubicin.HCl
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
    		[PMID: 25529734]
    MDA-MB-231 IC50
    4.4 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-231 cells after 4 days by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 4 days by MTT assay
    		[PMID: 20619511]
    MDA-MB-231 IC50
    5.18 μM
    Compound: Adriamycin
    Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by Ez-cytox assay
    Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by Ez-cytox assay
    		[PMID: 31398033]
    MDA-MB-231 IC50
    < 0.068 mg/mL
    Compound: Doxorubicin
    Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
    		[PMID: 22142614]
    MDA-MB-435 GI50
    < 0.1 μM
    Compound: ADR
    Anticancer activity against human MDA-MB-435 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    Anticancer activity against human MDA-MB-435 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    		[PMID: 26994845]
    MDA-MB-435 GI50
    < 0.1 μM
    Compound: Adriamycin
    Anticancer activity against human MDA-MB-435 cells assessed as cell growth inhibition by sulforhodamine B assay
    Anticancer activity against human MDA-MB-435 cells assessed as cell growth inhibition by sulforhodamine B assay
    		[PMID: 35694689]
    MDA-MB-435 IC50
    0.77 μg/mL
    Compound: Dox
    Cytotoxicity against Homo sapiens (human) MDA-MB-435 cells assessed as inhibition of cell viability by MTT assay
    Cytotoxicity against Homo sapiens (human) MDA-MB-435 cells assessed as inhibition of cell viability by MTT assay
    		10.1007/s00044-013-0486-7
    MDA-MB-435 IC50
    0.93 μg/mL
    Compound: Dox
    Cytotoxicity against Homo sapiens (human) MDA-MB-435 cells assessed as inhibition of cell viability by SRB assay
    Cytotoxicity against Homo sapiens (human) MDA-MB-435 cells assessed as inhibition of cell viability by SRB assay
    		10.1007/s00044-013-0486-7
    MDA-MB-436 IC50
    2.03 μM
    Compound: Adriamycin
    Antiproliferative activity against human MDA-MB-436 cells measured after 72 hrs by Ez-cytox assay
    Antiproliferative activity against human MDA-MB-436 cells measured after 72 hrs by Ez-cytox assay
    		[PMID: 31398033]
    MDA-MB-468 EC50
    0.7 μM
    Compound: Adriamycin
    Antiproliferative activity against human ER-triple negative MDA-MB-468 cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human ER-triple negative MDA-MB-468 cells measured after 48 hrs by MTT assay
    		[PMID: 27344488]
    MDA-MB-468 GI50
    10.5 μM
    Compound: ADR
    Anticancer activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    Anticancer activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    		[PMID: 26994845]
    MDA-MB-468 IC50
    2.15 μM
    Compound: Adriamycin
    Cytotoxicity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay
    Cytotoxicity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay
    		[PMID: 27707625]
    MG-63 IC50
    2.2 μM
    Compound: Adriamycin
    Cytotoxicity against human MG63 cells by MTT assay
    Cytotoxicity against human MG63 cells by MTT assay
    		[PMID: 27704808]
    MG-63 IC50
    3.4 μM
    Compound: Adriamycin
    Cytotoxicity against human MG63 cells by MTT assay
    Cytotoxicity against human MG63 cells by MTT assay
    		[PMID: 23477504]
    MG-63 IC50
    5.2 μM
    Compound: Adriamycin
    Growth inhibition of human MG63 cells by MTT method
    Growth inhibition of human MG63 cells by MTT method
    		[PMID: 25611131]
    MGC-803 IC50
    0.2 μM
    Compound: ADM
    Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
    Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
    		[PMID: 29985604]
    MGC-803 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human MGC803 cells after 24 hrs by SRB method
    Cytotoxicity against human MGC803 cells after 24 hrs by SRB method
    		[PMID: 31904949]
    MGC-803 IC50
    0.2 μM
    Compound: Dox
    Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
    Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay
    		[PMID: 26506221]
    MGC-803 IC50
    0.48 μM
    Compound: Adriamycin
    Anticancer activity against human MGC-803 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
    Anticancer activity against human MGC-803 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
    		[PMID: 35367708]
    MGC-803 IC50
    0.71 μM
    Compound: ADM
    Growth inhibition of human MGC803 cells after 72 hrs by MTT assay
    Growth inhibition of human MGC803 cells after 72 hrs by MTT assay
    		[PMID: 25064351]
    MGC-803 IC50
    0.74 μM
    Compound: ADM
    Cytotoxicity against human MGC803 cells
    Cytotoxicity against human MGC803 cells
    		[PMID: 31129455]
    MGC-803 IC50
    2.4 μM
    Compound: DOX
    Anticancer activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Anticancer activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 38389893]
    MGC-803 IC50
    2.53 μM
    Compound: Adriamycin
    Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay
    Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay
    		[PMID: 21144747]
    MGC-803 IC50
    2.56 μM
    Compound: Dox
    Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay
    Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay
    		[PMID: 22318158]
    MIA PaCa-2 ED50
    6.3 μM
    Compound: Adriamycin
    Cytotoxicity against PACA-2 cell line in the purdue cell culture screen was determined
    Cytotoxicity against PACA-2 cell line in the purdue cell culture screen was determined
    		[PMID: 10091695]
    MIA PaCa-2 GI50
    80 μg/mL
    Compound: Adriamycin
    Growth inhibition of human MIA PaCa-2 cells incubated for 48 hrs by SRB assay
    Growth inhibition of human MIA PaCa-2 cells incubated for 48 hrs by SRB assay
    		[PMID: 38830427]
    MIA PaCa-2 IC50
    0.25 μM
    Compound: Adriamycin
    Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth by CCK-8 assay
    Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth by CCK-8 assay
    		[PMID: 36583957]
    MKN-1 IC50
    0.12 μM
    Compound: ADR
    Antiproliferative activity against human MKN-1 cells incubated for 72 hrs by SRB method
    Antiproliferative activity against human MKN-1 cells incubated for 72 hrs by SRB method
    		[PMID: 39054645]
    MOLT-4 GI50
    < 0.1 μM
    Compound: ADR
    Cytotoxicity against Homo sapiens (human) MOLT4 cells after 48 hr by SRB assay
    Cytotoxicity against Homo sapiens (human) MOLT4 cells after 48 hr by SRB assay
    		10.1007/s00044-012-0423-1
    MOLT-4 IC50
    0.07 μM
    Compound: Dox
    Cytotoxicity against human MOLT4 cells after 48 hrs by Alamar blue assay
    Cytotoxicity against human MOLT4 cells after 48 hrs by Alamar blue assay
    		[PMID: 25064348]
    MOLT-4F GI50
    0.277 μg/mL
    Compound: ADR
    Antitumor activity against human MOLT4F cells
    Antitumor activity against human MOLT4F cells
    		[PMID: 20045644]
    MRC5 IC50
    1.54 μg/mL
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability
    Cytotoxicity against human MRC5 cells assessed as reduction in cell viability
    		[PMID: 38229749]
    MV4-11 IC50
    0.006 μM
    Compound: Doxorubicin HCl
    Antiproliferative activity against Homo sapiens (human) MV411 cells after 72 hr by MTT assay
    Antiproliferative activity against Homo sapiens (human) MV411 cells after 72 hr by MTT assay
    		10.1007/s00044-012-0443-x
    MV4-11 IC50
    0.006 μM
    Compound: Doxorubicin HCl
    Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay
    Antiproliferative activity against human MV4-11 cells after 72 hrs by MTT assay
    		[PMID: 22748378]
    MV4-11 IC50
    0.006 μM
    Compound: Doxorubicin HCl
    Cytotoxicity against human MV4-11 cells assessed as cell viability after 72 hrs by MTT assay
    Cytotoxicity against human MV4-11 cells assessed as cell viability after 72 hrs by MTT assay
    		[PMID: 24686018]
    MV4-11 IC50
    0.14 μM
    Compound: Adriamycin
    Cytotoxicity against human MV4-11 cells assessed as inhibition of cell growth measured after 72 hrs by Celltiter-Glo assay
    Cytotoxicity against human MV4-11 cells assessed as inhibition of cell growth measured after 72 hrs by Celltiter-Glo assay
    		[PMID: 33356258]
    NB-4 IC50
    0.4 μM
    Compound: Adriamycin
    Cytotoxicity against human NB4 cells after 72 hrs by MTT assay
    Cytotoxicity against human NB4 cells after 72 hrs by MTT assay
    		[PMID: 28418245]
    NCI-H1299 IC50
    0.8 μM
    Compound: Adriamycin
    Cytotoxicity in human NCI-H1299 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human NCI-H1299 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31268321]
    NCI-H1299 IC50
    4.7 μM
    Compound: Adriamycin
    Cytotoxicity against human NCI-H12199 cells assessed as cell viability inhibition for 48 hrs by MTT assay
    Cytotoxicity against human NCI-H12199 cells assessed as cell viability inhibition for 48 hrs by MTT assay
    		[PMID: 33913326]
    NCI-H187 IC50
    0.086 μM
    Compound: doxorubicin hydrochloride
    Cytotoxicity against human NCI-H187 cells after 45 hrs by resazurin microplate assay
    Cytotoxicity against human NCI-H187 cells after 45 hrs by resazurin microplate assay
    		[PMID: 20364867]
    NCI-H187 IC50
    0.23 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human NCI-H187 cells after 45 hrs by resazurin microplate assay
    Cytotoxicity against human NCI-H187 cells after 45 hrs by resazurin microplate assay
    		[PMID: 21473608]
    NCI-H187 IC50
    0.25 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human NCI-H187 cells by resazurin microplate assay
    Cytotoxicity against human NCI-H187 cells by resazurin microplate assay
    		[PMID: 21995505]
    NCI-H1975 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human NCI-H1975 cells after 24 hrs by sulforhodamine B assay
    Cytotoxicity against human NCI-H1975 cells after 24 hrs by sulforhodamine B assay
    		[PMID: 28418245]
    NCI-H1975 IC50
    0.8 μM
    Compound: Dox
    Cytotoxicity against human NCI-H1975 cells after 72 hrs by MTT assay
    Cytotoxicity against human NCI-H1975 cells after 72 hrs by MTT assay
    		[PMID: 26506221]
    NCI-H226 GI50
    < 0.1 μM
    Compound: ADR
    Anticancer activity against human NCI-H226 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    Anticancer activity against human NCI-H226 cells assessed as inhibition of cell growth incubated for 48 hrs by SRB assay
    		[PMID: 26994845]
    NCI-H226 IC50
    0.3 μM
    Compound: Adriamycin
    Antiproliferative activity against human NCI-H226 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    Antiproliferative activity against human NCI-H226 cells assessed as reduction in cell viability after 24 hrs by CCK8 assay
    		[PMID: 31397570]
    NCI-H23 GI50
    0.08 μM
    Compound: Adriamycin
    Cytotoxicity against human NCI-H23 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human NCI-H23 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay
    		[PMID: 29878761]
    NCI-H23 GI50
    0.08 μM
    Compound: Adriamycin
    Growth inhibition of human NCI-H23 cells by SRB assay
    Growth inhibition of human NCI-H23 cells by SRB assay
    		[PMID: 36040099]
    NCI-H23 GI50
    0.14 μM
    Compound: ADR
    Cytotoxicity against human NCI-H23 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Cytotoxicity against human NCI-H23 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 31668073]
    NCI-H23 IC50
    0.09 μM
    Compound: ADR
    Cytotoxicity against human NCI-H23 cells by colorimetric method
    Cytotoxicity against human NCI-H23 cells by colorimetric method
    		[PMID: 32916298]
    NCI-H23 IC50
    0.16 μM
    Compound: ADR
    Cytotoxicity against human NCI-H23 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method
    Cytotoxicity against human NCI-H23 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method
    		[PMID: 35302779]
    NCI-H23 IC50
    0.49 μM
    Compound: Adriamycin
    Anti-proliferative activity against human NCI-H23 cells by XTT assay
    Anti-proliferative activity against human NCI-H23 cells by XTT assay
    		[PMID: 25442319]
    NCI-H3255 IC50
    1.5 μM
    Compound: Adriamycin
    Cytotoxicity against human NCI-H3255 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human NCI-H3255 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 34797067]
    NCI-H358 IC50
    < 5 μM
    Compound: Adriamycin
    Antiproliferative activity against human NCI-H358 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    Antiproliferative activity against human NCI-H358 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    		[PMID: 35586422]
    NCI-H446 IC50
    0.6 μM
    Compound: Adriamycin
    Cytotoxicity against human NCI-H446 cells by SRB assay
    Cytotoxicity against human NCI-H446 cells by SRB assay
    		[PMID: 38662578]
    NCI-H446 IC50
    1.7 μM
    Compound: Adriamycin
    Cytotoxicity against human NCI-H446 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human NCI-H446 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 34797067]
    NCI-H460 IC50
    0.24 μM
    Compound: adriamycin
    Cytotoxic activity against human H460 cells by MTT method
    Cytotoxic activity against human H460 cells by MTT method
    		[PMID: 25739048]
    NCI-H460 IC50
    0.98 μM
    Compound: Adriamycin
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 26933756]
    NCI-H460 IC50
    1 μM
    Compound: Adriamycin
    Cytotoxicity against human NCI-H460 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human NCI-H460 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay
    		[PMID: 28206772]
    NCI-N87 IC50
    0.71 μM
    Compound: Adriamycin
    Cytotoxicity against human NCI-N87 cells assessed as reduction in cell growth after 72 hrs by CCK8 assay
    Cytotoxicity against human NCI-N87 cells assessed as reduction in cell growth after 72 hrs by CCK8 assay
    		[PMID: 27484510]
    NCI/ADR-RES EC50
    > 10 μM
    Compound: Adriamycin
    Antiproliferative activity against human MCF7/ADR cells measured after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7/ADR cells measured after 48 hrs by MTT assay
    		[PMID: 27344488]
    NCI/ADR-RES ED50
    1.5 μM
    Compound: Adriamycin
    Cytotoxicity against MCF-7ADR cell line in the purdue cell culture screen was determined
    Cytotoxicity against MCF-7ADR cell line in the purdue cell culture screen was determined
    		[PMID: 10091695]
    NCI/ADR-RES GI50
    0.52 μM
    Compound: Adr
    Antiproliferative activity against human MCF7/ADR cells after 96 hrs by MTT assay
    Antiproliferative activity against human MCF7/ADR cells after 96 hrs by MTT assay
    		[PMID: 26741854]
    NCI/ADR-RES GI50
    0.54 μM
    Compound: Adr
    Antiproliferative activity against human MCF7/ADR cells after 96 hrs by MTT assay
    Antiproliferative activity against human MCF7/ADR cells after 96 hrs by MTT assay
    		[PMID: 29102180]
    NCI/ADR-RES IC50
    112.8 μM
    Compound: Adriamycin
    Antiproliferative activity against human MCF7ADR cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    Antiproliferative activity against human MCF7ADR cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
    		[PMID: 37856840]
    NCI/ADR-RES IC50
    2.9 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7/ADR cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7/ADR cells after 72 hrs by MTT assay
    		[PMID: 29286660]
    NCI/ADR-RES IC50
    232.5 μM
    Compound: ADR
    Antiproliferative activity against adriamycin resistant human MCF7/ADR cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Antiproliferative activity against adriamycin resistant human MCF7/ADR cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 34649064]
    NCI/ADR-RES IC50
    24.92 μM
    Compound: ADR
    Antiproliferative activity against human NCI-ADR-RES cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Antiproliferative activity against human NCI-ADR-RES cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 35390712]
    NCI/ADR-RES IC50
    25996 nM
    Compound: ADR
    Reversal effect on P-gp-mediated multidrug resistance in human NCI/ADR-RES cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay
    Reversal effect on P-gp-mediated multidrug resistance in human NCI/ADR-RES cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay
    		[PMID: 38502936]
    NCI/ADR-RES IC50
    39.52 μM
    Compound: ADR
    Cytotoxicity against human MCF7/ADR cells after 72 hrs by MTT assay
    Cytotoxicity against human MCF7/ADR cells after 72 hrs by MTT assay
    		[PMID: 30677614]
    NCI/ADR-RES IC50
    44.9 μM
    Compound: ADR
    Antiproliferative activity against human MCF7/ADR cells after 72 hrs by sulforhodamine B assay
    Antiproliferative activity against human MCF7/ADR cells after 72 hrs by sulforhodamine B assay
    		[PMID: 20353152]
    NCI/ADR-RES IC50
    50.74 μM
    Compound: Adriamycin
    Growth inhibition of human MCF7/ADR cells after 48 hrs by MTT assay
    Growth inhibition of human MCF7/ADR cells after 48 hrs by MTT assay
    		[PMID: 29903663]
    NCI/ADR-RES IC50
    5300 nM
    Compound: adriamycin
    Antiproliferative activity against adriamycin resistant human MCF7/ADR cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    Antiproliferative activity against adriamycin resistant human MCF7/ADR cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
    		[PMID: 25208345]
    NCI/ADR-RES IC50
    54749.1 nM
    Compound: Adriamycin
    Antiproliferative activity against human MCF7/ADR cells after 48 to 72 hrs by MTT assay
    Antiproliferative activity against human MCF7/ADR cells after 48 to 72 hrs by MTT assay
    		[PMID: 29754076]
    NCI/ADR-RES IC50
    54750 nM
    Compound: Adriamycin
    Antiproliferative activity against human MCF7/ADR cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7/ADR cells after 48 hrs by MTT assay
    		[PMID: 28763646]
    NCI/ADR-RES IC50
    58.8 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7/ADR cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    Cytotoxicity against human MCF7/ADR cells assessed as inhibition of cell survival rate after 48 hrs by MTT assay
    		[PMID: 27240278]
    NCI/ADR-RES IC50
    8153 nM
    Compound: Adriamycin
    Cytotoxicity against P-gp overexpressing human MCF7/ADR cells assessed as reduction in cell growth after 24 hrs by MTT assay
    Cytotoxicity against P-gp overexpressing human MCF7/ADR cells assessed as reduction in cell growth after 24 hrs by MTT assay
    		[PMID: 27213819]
    NCI/ADR-RES IC50
    8216 nM
    Compound: Adriamycin
    Cytotoxicity in human NCI-ADR-RES assessed as inhibition in cell growth measured after 24 hrs by MTT assay
    Cytotoxicity in human NCI-ADR-RES assessed as inhibition in cell growth measured after 24 hrs by MTT assay
    		[PMID: 35084853]
    NCI/ADR-RES IC50
    85.14 μM
    Compound: ADR
    Antiproliferative activity against human MCF7/ADR cells after 48 hrs by MTT assay
    Antiproliferative activity against human MCF7/ADR cells after 48 hrs by MTT assay
    		[PMID: 35339100]
    NCI/ADR-RES IC50
    8631 nM
    Compound: Adriamycin
    Antiproliferative activity against human MCF7ADR cells assessed as reduction in cell viability measured after 72 hrs
    Antiproliferative activity against human MCF7ADR cells assessed as reduction in cell viability measured after 72 hrs
    		[PMID: 38430854]
    NCI/ADR-RES IC50
    > 50 μM
    Compound: Adriamycin
    Cytotoxicity against human MCF7/ADR cells after 72 hrs
    Cytotoxicity against human MCF7/ADR cells after 72 hrs
    		[PMID: 28720329]
    NIH3T3 IC50
    0.34 μM
    Compound: ADR
    Cytotoxicity against mouse 3T3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against mouse 3T3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31977207]
    NIH3T3 IC50
    0.36 μM
    Compound: ADR
    Cytotoxicity against mouse 3T3 cells measured after 72 hrs by MTT assay
    Cytotoxicity against mouse 3T3 cells measured after 72 hrs by MTT assay
    		[PMID: 30739826]
    NIH3T3 IC50
    0.55 μM
    Compound: ADR
    Cytotoxicity against mouse 3T3 cells
    Cytotoxicity against mouse 3T3 cells
    		[PMID: 30006167]
    NIH3T3 IC50
    1.08 μM
    Compound: DOX
    Cytotoxicity against BALB mouse 3T3 cells after 72 hrs by SRB assay
    Cytotoxicity against BALB mouse 3T3 cells after 72 hrs by SRB assay
    		[PMID: 22574992]
    NUGC-3 GI50
    0.07 μM
    Compound: Adriamycin
    Cytotoxicity against human NUGC3 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human NUGC3 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay
    		[PMID: 29878761]
    NUGC-3 GI50
    0.08 μM
    Compound: Adriamycin
    Growth inhibition of human NUGC-3 cells by SRB assay
    Growth inhibition of human NUGC-3 cells by SRB assay
    		[PMID: 36040099]
    NUGC-3 GI50
    0.15 μM
    Compound: ADR
    Cytotoxicity against human NUGC3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Cytotoxicity against human NUGC3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 31668073]
    NUGC-3 IC50
    0.15 μM
    Compound: ADR
    Cytotoxicity against human NUGC-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method
    Cytotoxicity against human NUGC-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method
    		[PMID: 35302779]
    NUGC-3 IC50
    0.38 μM
    Compound: Adriamycin
    Anti-proliferative activity against human NUGC3 cells by XTT assay
    Anti-proliferative activity against human NUGC3 cells by XTT assay
    		[PMID: 25442319]
    OS-RC-2 IC50
    < 1 μM
    Compound: Adriamycin
    Cytotoxicity against human OS-RC2 cells by MTT assay
    Cytotoxicity against human OS-RC2 cells by MTT assay
    		[PMID: 20627721]
    OS-RC-2 IC50
    < 1.3 μM
    Compound: Adriamycin
    Cytotoxicity against human OS-RC2 cells by MTT assay
    Cytotoxicity against human OS-RC2 cells by MTT assay
    		[PMID: 21875764]
    OVCAR-3 GI50
    < 0.1 μM
    Compound: Adriamycin
    Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition by sulforhodamine B assay
    Anticancer activity against human OVCAR-3 cells assessed as cell growth inhibition by sulforhodamine B assay
    		[PMID: 35694689]
    OVCAR-8 GI50
    0.15 μM
    Compound: ADR
    Cytotoxicity against human OVCAR8 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human OVCAR8 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21194809]
    P388 IC50
    0.1 μg/mL
    Compound: adriamycin HCl
    Antitumor activity against mouse P388 cells
    Antitumor activity against mouse P388 cells
    		[PMID: 10579858]
    P388 IC50
    0.3 μM
    Compound: Adriamycin
    Cytotoxicity against mouse p388 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Cytotoxicity against mouse p388 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 33301677]
    P388 IC50
    1.14 x 10-5 μM
    Compound: Adiramycin
    Anticancer activity against mouse P388 cells assessed as cell growth inhibition
    Anticancer activity against mouse P388 cells assessed as cell growth inhibition
    		[PMID: 33940466]
    P388 IC50
    17 nM
    Compound: Doxorubicin HCl
    In vitro inhibitory activity against cancerous P388 cell line
    In vitro inhibitory activity against cancerous P388 cell line
    		[PMID: 14736253]
    PANC-1 GI50
    0.24 μM
    Compound: DOX HCl
    Growth inhibition against human PANC1 cells after 72 hrs by inverted microscopy
    Growth inhibition against human PANC1 cells after 72 hrs by inverted microscopy
    		[PMID: 23353738]
    PANC-1 IC50
    0.48 μM
    Compound: Adriamycin
    Cytotoxicity against human PANC1 cells after 72 hrs under normoxic condition by MTT assay
    Cytotoxicity against human PANC1 cells after 72 hrs under normoxic condition by MTT assay
    		[PMID: 29656202]
    PANC-1 IC50
    0.9 μM
    Compound: ADM
    Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
    		[PMID: 35380848]
    PANC-1 IC50
    1.7 μM
    Compound: Adriamycin
    Cytotoxicity against human PANC1 cells after 72 hrs under hypoxic condition by MTT assay
    Cytotoxicity against human PANC1 cells after 72 hrs under hypoxic condition by MTT assay
    		[PMID: 29656202]
    PANC-1 IC50
    2.11 μM
    Compound: ADR
    Antiproliferative activity against human PANC1 cells after 72 hrs by MTT assay
    Antiproliferative activity against human PANC1 cells after 72 hrs by MTT assay
    		[PMID: 30006167]
    PC-3 ED50
    5.7 μM
    Compound: Adriamycin
    Cytotoxicity against PC-3 cell line in the purdue cell culture screen was determined
    Cytotoxicity against PC-3 cell line in the purdue cell culture screen was determined
    		[PMID: 10091695]
    PC-3 GI50
    0.09 μM
    Compound: Adriamycin
    Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay
    Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation measured after 72 hrs by sulforhodamine B assay
    		[PMID: 29878761]
    PC-3 GI50
    0.09 μM
    Compound: Adriamycin
    Growth inhibition of human PC-3 cells by SRB assay
    Growth inhibition of human PC-3 cells by SRB assay
    		[PMID: 36040099]
    PC-3 GI50
    0.14 μM
    Compound: ADR
    Cytotoxicity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    Cytotoxicity against human PC3 cells assessed as cell growth inhibition measured after 48 hrs by SRB assay
    		[PMID: 31668073]
    PC-3 GI50
    0.16 μM
    Compound: ADR
    Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
    Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
    		[PMID: 20554354]
    PC-3 GI50
    0.16 μM
    Compound: ADR
    Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay
    		[PMID: 21194809]
    PC-3 GI50
    1.1 μM
    Compound: Doxorubicin hydrochloride
    Growth inhibition of human PC3 cells by colorimetric MTT assay
    Growth inhibition of human PC3 cells by colorimetric MTT assay
    		[PMID: 25736997]
    PC-3 GI50
    1.81 μM
    Compound: ADR
    Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
    Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
    		[PMID: 20444601]
    PC-3 GI50
    1.81 μM
    Compound: ADR
    Cytotoxicity against human PC3 cells by sulforhodamine B method
    Cytotoxicity against human PC3 cells by sulforhodamine B method
    		[PMID: 21459581]
    PC-3 GI50
    < 0.1 μM
    Compound: Adriamycin
    Anticancer activity against human PC-3 cells assessed as cell growth inhibition by sulforhodamine B assay
    Anticancer activity against human PC-3 cells assessed as cell growth inhibition by sulforhodamine B assay
    		[PMID: 35694689]
    PC-3 IC50
    0.02 μM
    Compound: Adriamycin
    Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
    Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
    		[PMID: 25259515]
    PC-3 IC50
    0.09 μM
    Compound: ADR
    Cytotoxicity against human PC3 cells by colorimetric method
    Cytotoxicity against human PC3 cells by colorimetric method
    		[PMID: 32916298]
    PC-3 IC50
    0.16 μM
    Compound: ADR
    Cytotoxicity against human PC-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method
    Cytotoxicity against human PC-3 cells assessed as cell growth inhibition incubated for 48 hrs by SRB method
    		[PMID: 35302779]
    PC-3 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability by SRB assay
    		[PMID: 32840364]
    PC-3 IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human PC-3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    Cytotoxicity against human PC-3 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay
    		[PMID: 34282909]
    PC-3 IC50
    0.38 μM
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 33774342]
    PC-3 IC50
    0.4 μM
    Compound: ADR
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
    		[PMID: 35762988]
    PC-3 IC50
    0.4 μM
    Compound: Adriamycin
    Cytotoxicity against human PC-3 cells assessed as cell viability inhibition for 48 hrs by MTT assay
    Cytotoxicity against human PC-3 cells assessed as cell viability inhibition for 48 hrs by MTT assay
    		[PMID: 33913326]
    PC-3 IC50
    0.4 μM
    Compound: Adriamycin
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 34797067]
    PC-3 IC50
    0.42 μM
    Compound: Adriamycin
    Cytotoxicity against human PC3 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human PC3 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 29215886]
    PC-3 IC50
    0.5 μM
    Compound: Adriamycin
    Anti-proliferative activity against human PC3 cells by XTT assay
    Anti-proliferative activity against human PC3 cells by XTT assay
    		[PMID: 25442319]
    PC-3 IC50
    0.68 μM
    Compound: Adriamycin
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 21123066]
    PC-3 IC50
    0.8 μM
    Compound: ADM
    Growth inhibition of human PC3 cells after 72 hrs by MTT assay
    Growth inhibition of human PC3 cells after 72 hrs by MTT assay
    		[PMID: 25064351]
    PC-3 IC50
    0.8 μM
    Compound: Adriamycin
    Cytotoxicity against human PC3 cells after 24 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 24 hrs by MTT assay
    		[PMID: 30049584]
    PC-3 IC50
    1 μM
    Compound: ADM
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
    		[PMID: 29985604]
    PC-3 IC50
    1.01 μM
    Compound: ADM
    Cytotoxicity against human PC3 cells
    Cytotoxicity against human PC3 cells
    		[PMID: 31129455]
    PC-3 IC50
    1.18 μM
    Compound: Dox
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
    		[PMID: 22318158]
    PC-3 IC50
    11.74 μM
    Compound: Adriamycin
    Cytotoxicity against human PC3 cells after 24 hrs by MTT assay
    Cytotoxicity against human PC3 cells after 24 hrs by MTT assay
    		[PMID: 25226363]
    PC-3 IC50
    15.17 μM
    Compound: Adriamycin
    Cytotoxicity against docetaxel-resistant human PC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against docetaxel-resistant human PC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 27318123]
    PC-3 IC50
    16.89 μM
    Compound: Adriamycin
    Antiproliferative activity against paclitaxel-resistant human PC3 cells after 48 hrs by MTT assay
    Antiproliferative activity against paclitaxel-resistant human PC3 cells after 48 hrs by MTT assay
    		[PMID: 28222318]
    PC-3 IC50
    < 1 μM
    Compound: Adriamycin
    Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 24 hrs by CCK-8 assay
    		[PMID: 28757067]
    PLC-PRF-5 IC50
    1.9 μM
    Compound: Adriamycin
    Cytotoxicity against human PLC/PRF/5 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human PLC/PRF/5 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31013087]
    Panel (12 tumour cell lines) IC50
    0.007 μg/mL
    Compound: Adriamycin
    Cytotoxicity against human Panel (12 tumour cell lines)
    Cytotoxicity against human Panel (12 tumour cell lines)
    		[PMID: 33831559]
    QG-56 IC50
    2.5 μM
    Compound: Adriamycin
    Cytotoxicity against human QG56 cells assessed as cell viability after 48 hrs by MTT assay
    Cytotoxicity against human QG56 cells assessed as cell viability after 48 hrs by MTT assay
    		[PMID: 26810315]
    QG-56 IC50
    2.5 μM
    Compound: Adriamycin
    Cytotoxicity against human QG56 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human QG56 cells assessed as decrease in cell viability after 48 hrs by MTT assay
    		[PMID: 27318975]
    SAOS-2 IC50
    4.2 μM
    Compound: Adriamycin
    Growth inhibition of human Saos2 cells by MTT method
    Growth inhibition of human Saos2 cells by MTT method
    		[PMID: 25611131]
    SF-126 IC50
    0.26 μM
    Compound: ADR
    Antiproliferative activity against human SF126 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human SF126 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31977207]
    SGC-7901 IC50
    0.078 μg/mL
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human SGC7901 cells after 20 hrs by MTT assay
    Cytotoxicity against human SGC7901 cells after 20 hrs by MTT assay
    		[PMID: 21247667]
    SGC-7901 IC50
    0.078 μg/mL
    Compound: Doxorubicin hydrochloride
    Cytotoxicity against human SGC7901 cells assessed as cell mortality after 20 hrs by MTT assay
    Cytotoxicity against human SGC7901 cells assessed as cell mortality after 20 hrs by MTT assay
    		[PMID: 21296573]
    SGC-7901 IC50
    0.72 μM
    Compound: Adriamycin
    Anticancer activity against human SGC-7901 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
    Anticancer activity against human SGC-7901 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
    		[PMID: 35367708]
    SGC-7901 IC50
    4.12 μM
    Compound: ADM
    Antiproliferative activity against human SGC7901 cells after 72 hrs by MTT assay
    Antiproliferative activity against human SGC7901 cells after 72 hrs by MTT assay
    		[PMID: 29232583]
    SH-SY5Y IC50
    0.1 μM
    Compound: ADM
    Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay
    Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay
    		[PMID: 29985604]
    SH-SY5Y IC50
    0.1 μM
    Compound: Adriamycin
    Cytotoxicity against human SH-SY5Y cells after 24 hrs by SRB method
    Cytotoxicity against human SH-SY5Y cells after 24 hrs by SRB method
    		[PMID: 31904949]
    SH-SY5Y IC50
    0.5 μM
    Compound: Adriamycin
    Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability by SRB assay
    		[PMID: 32840364]
    SK-BR-3 GI50
    65.5 nM
    Compound: Doxorubicin HCl
    Growth inhibition of human SKBR3 cells after 72 hrs by SRB assay
    Growth inhibition of human SKBR3 cells after 72 hrs by SRB assay
    		[PMID: 22607205]
    SK-MEL-28 IC50
    0.5 μg/mL
    Compound: adriamycin HCl
    Antitumor activity against human SK MEL28 cells
    Antitumor activity against human SK MEL28 cells
    		[PMID: 10579858]
    SK-MEL-5 GI50
    0.481 μg/mL
    Compound: ADR
    Antitumor activity against human SK-MEL-5 cells
    Antitumor activity against human SK-MEL-5 cells
    		[PMID: 20045644]
    SK-OV-3 IC50
    0.48 μM
    Compound: Adriamycin
    Antiproliferative activity against human SK-OV-3 cells assessed as suppression of cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human SK-OV-3 cells assessed as suppression of cell growth incubated for 72 hrs by SRB assay
    		[PMID: 36764122]
    SMMC-7721 IC50
    0.46 μM
    Compound: Adriamycin
    Anticancer activity against human SMMC-7721 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
    Anticancer activity against human SMMC-7721 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
    		[PMID: 35367708]
    SMMC-7721 IC50
    0.66 μM
    Compound: Adriamycin
    Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 29215886]
    SMMC-7721 IC50
    0.8 μM
    Compound: Adriamycin
    Cytotoxicity in human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31117521]
    SMMC-7721 IC50
    0.8 μM
    Compound: Adriamycin
    Cytotoxicity in human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31268321]
    SMMC-7721 IC50
    1.1 μM
    Compound: Adriamycin
    Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 31013087]
    SMMC-7721 IC50
    2.2 μM
    Compound: Adriamycin
    Cytotoxicity against human SMMC7721 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay
    Cytotoxicity against human SMMC7721 cells assessed as inhibition of growth incubated for 72 hrs by MTT assay
    		[PMID: 28206772]
    SMMC-7721 IC50
    2.24 μM
    Compound: Adriamycin
    Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay
    Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay
    		[PMID: 26933756]
    SMMC-7721 IC50
    2.67 μM
    Compound: ADM
    Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay
    Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay
    		[PMID: 29232583]
    SMMC-7721 IC50
    2.67 μM
    Compound: ADM
    Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human SMMC-7721 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 30739827]
    SNU1 IC50
    2.01 μM
    Compound: Adriamycin
    Anticancer activity against human SNU1 cells assessed as reduction in cell viability for 72 hrs by MTT assay
    Anticancer activity against human SNU1 cells assessed as reduction in cell viability for 72 hrs by MTT assay
    		[PMID: 35367708]
    SU.86.86 IC50
    0.33 μM
    Compound: Adriamycin
    Cytotoxicity against human SU-86-86 cells assessed as inhibition of cell growth by CCK-8 assay
    Cytotoxicity against human SU-86-86 cells assessed as inhibition of cell growth by CCK-8 assay
    		[PMID: 36583957]
    SW-620 IC50
    0.09 μM
    Compound: ADR
    Cytotoxicity against human SW620 cells by colorimetric method
    Cytotoxicity against human SW620 cells by colorimetric method
    		[PMID: 32916298]
    SW-620 IC50
    0.35 μM
    Compound: ADR
    Antiproliferative activity against human SW-620 cells incubated for 72 hrs by SRB method
    Antiproliferative activity against human SW-620 cells incubated for 72 hrs by SRB method
    		[PMID: 39054645]
    SW-620 IC50
    1.2 μM
    Compound: Adriamycin
    Cytotoxicity in human SW620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human SW620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31268321]
    SW-620 IC50
    < 5 μM
    Compound: Adriamycin
    Antiproliferative activity against human SW-620 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    Antiproliferative activity against human SW-620 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
    		[PMID: 35586422]
    SW480 IC50
    0.12 μM
    Compound: ADR
    Cytotoxicity against human SW480 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    Cytotoxicity against human SW480 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
    		[PMID: 38253024]
    SiHa GI50
    0.15 μM
    Compound: ADR
    Cytotoxicity against human SiHa cells after 48 hrs by SRB assay
    Cytotoxicity against human SiHa cells after 48 hrs by SRB assay
    		[PMID: 20554354]
    SiHa GI50
    0.17 μM
    Compound: ADR
    Cytotoxicity against human SiHa cells after 48 hrs by SRB assay
    Cytotoxicity against human SiHa cells after 48 hrs by SRB assay
    		[PMID: 20444601]
    SiHa GI50
    0.17 μM
    Compound: ADR
    Cytotoxicity against human SiHa cells by sulforhodamine B method
    Cytotoxicity against human SiHa cells by sulforhodamine B method
    		[PMID: 21459581]
    SiHa GI50
    1.9 μM
    Compound: ADR
    Anticancer activity against human SiHa cells after 48 hrs by SRB assay
    Anticancer activity against human SiHa cells after 48 hrs by SRB assay
    		[PMID: 20557981]
    T-24 IC50
    1.76 μM
    Compound: DOX
    Anticancer activity against human T-24 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    Anticancer activity against human T-24 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
    		[PMID: 38389893]
    T47D IC50
    0.04 μM
    Compound: ADM
    Antiproliferative activity against human T47D cells assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay
    Antiproliferative activity against human T47D cells assessed as reduction in cell viability after 96 hrs by sulforhodamine B assay
    		[PMID: 26866967]
    T47D IC50
    0.25 μM
    Compound: Adriamycin
    Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
    		[PMID: 28384547]
    T47D IC50
    0.3 μM
    Compound: Adriamycin
    Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
    		[PMID: 28068603]
    T47D IC50
    0.31 μM
    Compound: Adriamycin
    Antiproliferative activity against human T47D cells incubated for 72 hrs by CCK8 assay
    Antiproliferative activity against human T47D cells incubated for 72 hrs by CCK8 assay
    		[PMID: 29402741]
    T47D IC50
    0.31 μM
    Compound: Adriamycin
    Antiproliferative activity against human T47D cells after 72 hrs by EZ-CYTOX reagent based assay
    Antiproliferative activity against human T47D cells after 72 hrs by EZ-CYTOX reagent based assay
    		[PMID: 30262132]
    T47D IC50
    0.34 μM
    Compound: Adriamycin
    Antiproliferative activity against human T47D cells measured after 72 hrs by EZ-Cytox assay
    Antiproliferative activity against human T47D cells measured after 72 hrs by EZ-Cytox assay
    		[PMID: 31398033]
    T47D IC50
    0.41 μM
    Compound: Adriamycin
    Cytotoxicity against human T47D cells incubated from day 2 to day 4 by CCK8 assay
    Cytotoxicity against human T47D cells incubated from day 2 to day 4 by CCK8 assay
    		[PMID: 26022080]
    T47D IC50
    0.84 μM
    Compound: ADM
    Cytotoxicity against human T47D cells after 72 hrs by cell counting kit-8 analysis
    Cytotoxicity against human T47D cells after 72 hrs by cell counting kit-8 analysis
    		[PMID: 29174815]
    T47D IC50
    0.84 μM
    Compound: Adriamycin
    Antiproliferative activity against human T47D cells after 72 hrs by CCK-8 assay
    Antiproliferative activity against human T47D cells after 72 hrs by CCK-8 assay
    		[PMID: 29510948]
    T47D IC50
    1.29 μM
    Compound: Adriamycin
    Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
    		[PMID: 28633898]
    T47D IC50
    1.29 μM
    Compound: Adriamycin
    Antiproliferative activity against human T47D cells assessed as inhibition of cell proliferation incubated for 72 hrs by WST assay
    Antiproliferative activity against human T47D cells assessed as inhibition of cell proliferation incubated for 72 hrs by WST assay
    		[PMID: 36493620]
    T47D IC50
    1.34 μM
    Compound: Adriamycin
    Cytotoxicity against human T47D cells after 3 days by CCK8 assay
    Cytotoxicity against human T47D cells after 3 days by CCK8 assay
    		[PMID: 26927425]
    T47D IC50
    1.34 μM
    Compound: Adriamycin
    Cytotoxicity against human T47D cells after 48 hrs by CCK8 assay
    Cytotoxicity against human T47D cells after 48 hrs by CCK8 assay
    		[PMID: 26945111]
    T47D IC50
    1.34 μM
    Compound: Adriamycin
    Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
    		[PMID: 27643560]
    T47D IC50
    1.42 μM
    Compound: Adriamycin
    Cytotoxicity against human T47D cells assessed as reduction in cell growth after 72 hrs by CCK8 assay
    Cytotoxicity against human T47D cells assessed as reduction in cell growth after 72 hrs by CCK8 assay
    		[PMID: 27484510]
    T47D IC50
    1.48 μM
    Compound: Adriamycin
    Antiproliferative activity against human T47D cells after 72 hrs by EZ-Cytox colorimetric assay
    Antiproliferative activity against human T47D cells after 72 hrs by EZ-Cytox colorimetric assay
    		[PMID: 34678573]
    T47D IC50
    1.5 μM
    Compound: Adriamycin
    Antiproliferative activity against human T47D cells measured after 72 hrs by CCK8 assay
    Antiproliferative activity against human T47D cells measured after 72 hrs by CCK8 assay
    		[PMID: 27654394]
    T47D IC50
    2.18 μM
    Compound: Adriamycin
    Cytotoxicity against human T47D cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay
    Cytotoxicity against human T47D cells assessed as cell growth inhibition measured after 2 days by cell counting kit-8 assay
    		[PMID: 27707625]
    T47D IC50
    2.9 μM
    Compound: Adriamycin
    Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
    Antiproliferative activity against human T47D cells after 72 hrs by CCK8 assay
    		[PMID: 26988802]
    T47D IC50
    3.12 μM
    Compound: Adriamycin
    Cytotoxicity against human T47D cells after 4 days by CCK-8 assay
    Cytotoxicity against human T47D cells after 4 days by CCK-8 assay
    		[PMID: 25062006]
    T47D IC50
    4.59 μM
    Compound: Adriamycin
    Antiproliferative activity against human T47D cells assessed as inhibition of cell proliferation
    Antiproliferative activity against human T47D cells assessed as inhibition of cell proliferation
    		[PMID: 35123005]
    THP-1 IC50
    0.02 μM
    Compound: Adriamycin
    Cytotoxicity against human THP1 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay
    Cytotoxicity against human THP1 cells assessed as inhibition of cell growth after 48 hrs by sulforhodamine B assay
    		10.1039/C5MD00289C
    U-118-MG IC50
    0.09 μM
    Compound: ADR
    Antiproliferative activity against human U118MG cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human U118MG cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31977207]
    U-251 IC50
    0.157 μM
    Compound: Adriamycin
    Cytotoxicity against human U251 cells assessed as inhibition of proliferation incubated for 72 hrs by MTT assay
    Cytotoxicity against human U251 cells assessed as inhibition of proliferation incubated for 72 hrs by MTT assay
    		[PMID: 34237623]
    U-251 IC50
    2.8 μM
    Compound: Adriamycin
    Cytotoxicity in human U251 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human U251 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31268321]
    U-251 IC50
    2.9 μM
    Compound: Adriamycin
    Cytotoxicity in human U251 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human U251 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31117521]
    U-251 IC50
    48 μM
    Compound: ADR
    Antiproliferative activity against human U251 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human U251 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31977207]
    U-87MG ATCC IC50
    0.1 μM
    Compound: Adriamycin
    Cytotoxicity against human U87 cells after 24 hrs by SRB method
    Cytotoxicity against human U87 cells after 24 hrs by SRB method
    		[PMID: 31904949]
    U-87MG ATCC IC50
    0.11 μM
    Compound: Doxorubicin.HCl
    Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 48 hrs by MTT assay
    Cytotoxicity against human U87MG cells assessed as reduction in cell viability after 48 hrs by MTT assay
    		[PMID: 30223117]
    U-87MG ATCC IC50
    0.15 μM
    Compound: ADR
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTT assay
    		[PMID: 31977207]
    U-87MG ATCC IC50
    0.16 μM
    Compound: ADR
    Antiproliferative activity against human U87 cells after 72 hrs by MTT assay
    Antiproliferative activity against human U87 cells after 72 hrs by MTT assay
    		[PMID: 30006167]
    U-87MG ATCC IC50
    0.19 μM
    Compound: ADR
    Antiproliferative activity against human U-87 MG cells incubated for 72 hrs by SRB assay
    Antiproliferative activity against human U-87 MG cells incubated for 72 hrs by SRB assay
    		[PMID: 39054645]
    U-87MG ATCC IC50
    0.2 μM
    Compound: Adriamycin
    Cytotoxicity against human U87 cells assessed as reduction in cell viability by SRB assay
    Cytotoxicity against human U87 cells assessed as reduction in cell viability by SRB assay
    		[PMID: 32840364]
    U-87MG ATCC IC50
    0.57 μM
    Compound: Adriamycin
    Anticancer activity against human U87 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
    Anticancer activity against human U87 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay
    		[PMID: 35367708]
    U-87MG ATCC IC50
    1.1 μM
    Compound: Adriamycin
    Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
    		[PMID: 31117521]
    U-87MG ATCC IC50
    4.28 μM
    Compound: ADM
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    Antiproliferative activity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
    		[PMID: 30739827]
    UACC-62 GI50
    0.25 μg/mL
    Compound: Doxorubicin
    Cytotoxicity against human UACC62 cells assessed as growth inhibition by SRB assay
    Cytotoxicity against human UACC62 cells assessed as growth inhibition by SRB assay
    		[PMID: 24507920]
    Vero GI50
    0.02 μM
    Compound: ADR
    Cytotoxicity against African green monkey Vero cells after 72 hrs by sulforhodamine B assay
    Cytotoxicity against African green monkey Vero cells after 72 hrs by sulforhodamine B assay
    		[PMID: 28778369]
    Vero GI50
    19 μM
    Compound: Adriamycin
    Cytotoxicity against African green monkey Vero cells after 48 hrs by SRB assay
    Cytotoxicity against African green monkey Vero cells after 48 hrs by SRB assay
    		[PMID: 28258796]
    Vero GI50
    2 μM
    Compound: ADR
    Cytotoxicity against African green monkey Vero cells assessed as total inhibition of cell growth after 72 hrs by sulforhodamine B assay
    Cytotoxicity against African green monkey Vero cells assessed as total inhibition of cell growth after 72 hrs by sulforhodamine B assay
    		[PMID: 28778369]
    WI-38 IC50
    0.08 μM
    Compound: Adriamycin
    Cytotoxicity against human WI38 cells after 72 hrs by CCK8 assay
    Cytotoxicity against human WI38 cells after 72 hrs by CCK8 assay
    		[PMID: 27997206]
    WI-38 IC50
    0.7 μM
    Compound: ADM
    Cytotoxicity against human WI38 cells
    Cytotoxicity against human WI38 cells
    		[PMID: 17067155]
    WI-38 VA13 IC50
    0.4 μM
    Compound: ADM
    Cytotoxicity against human VA13 cells
    Cytotoxicity against human VA13 cells
    		[PMID: 17067155]
    YAPC IC50
    0.31 μM
    Compound: Adriamycin
    Cytotoxicity against human YAPC cells assessed as inhibition of cell growth by CCK-8 assay
    Cytotoxicity against human YAPC cells assessed as inhibition of cell growth by CCK-8 assay
    		[PMID: 36583957]
    ZR-75-1 GI50
    0.12 μM
    Compound: ADR
    Cytotoxicity against human ZR-75-1 cells after 48 hrs by SRB assay
    Cytotoxicity against human ZR-75-1 cells after 48 hrs by SRB assay
    		[PMID: 20554354]
    ZR-75-1 GI50
    1.79 μM
    Compound: ADR
    Cytotoxicity against human ZR-75-1 cells after 48 hrs by SRB assay
    Cytotoxicity against human ZR-75-1 cells after 48 hrs by SRB assay
    		[PMID: 20444601]
    ZR-75-1 GI50
    1.79 μM
    Compound: ADR
    Cytotoxicity against human ZR-75-1 cells by sulforhodamine B method
    Cytotoxicity against human ZR-75-1 cells by sulforhodamine B method
    		[PMID: 21459581]
    ZR-75-1 GI50
    < 0.1 μM
    Compound: ADR
    Anticancer activity against human ZR-75-1 cells after 48 hrs by SRB assay
    Anticancer activity against human ZR-75-1 cells after 48 hrs by SRB assay
    		[PMID: 20557981]
    体外研究
    (In Vitro)

    Doxorubicin (1-8 μM；24 和 48 小时) hydrochloride 以时间和剂量依赖性方式降低 MCF-10F、MCF-7 和 MDA-MB-231 细胞的活力[4]。
    Doxorubicin (1 μM；3 和 24 小时) hydrochloride 导致 Hct-116 人结肠癌细胞在 G0/G1 期减少和在 G2 期积累[5]。
    Doxorubicin (MCF-10F 和 MDA-MB-231 细胞为 1 μM，MCF-7 细胞为 4 μM；48 小时) hydrochloride 通过上调 Bax、caspase-8 和 caspase-3 以及下调 Bcl-2 蛋白表达诱导细胞凋亡[4]。
    Doxorubicin (5 μM; 10-30 分钟) hydrochloride 在 B16-F10 黑色素瘤细胞系 CRL-6475 细胞中能以时间依赖方式在细胞中积累，且可以通过绿色或红色荧光来进行检测 (绿色荧光的检测灵敏度更高), 最大激发波长 (λex) 和最大发射波长 (λem) 分别为 470 nm 和 560 nm[8]。
    注意：
    Doxorubicin hydrochloride 适合中性或者弱酸性的溶剂，不建议使用 PBS (PH 7.4) 进行溶解，可能会影响溶解效果。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Doxorubicin hydrochloride 相关抗体:

    Cell Viability Assay[4]

    Cell Line: Breast cancer cell lines MCF-10F, MCF-7 and MDA-MB-231
    Concentration: 0, 1, 2, 4 and 8 μM
    Incubation Time: 24 and 48 hours
    Result: IC50 was 1 μM for both MCF-10F and MDA-MB-231 cell lines.
    IC50 was 4 μM for MCF-7 cell line.

    Cell Cycle Analysis[5]

    Cell Line: Hct-116 human colon carcinoma cells
    Concentration: 1 μM
    Incubation Time: 3 hours and 24 hours
    Result: Both, bolus (3 h) and continuous (24 h) incubation led to a significant reduction of cells in G0/G1 and accumulation in G2 phase.

    Western Blot Analysis[4]

    Cell Line: Breast cancer cell lines MCF-10F, MCF-7 and MDA-MB-231
    Concentration: 1 μM for MCF-10F and MDA-MB-231 cells, 4 μM for MCF-7 cells
    Incubation Time: 48 hours
    Result: Bax protein expression was upregulated in MCF-10F and MDA-MB-231 cell lines but MCF-7 cells did not show any significant increase.
    Caspase-8 gene expression was upregulated in MCF-10F, but it was downregulated in MCF-7 and MDA-MB-231 cells.
    体内研究
    (In Vivo)

    注意：
    请勿仅参考一篇文章来确定实验条件。建议在正式实验前，通过预实验确定最佳实验条件 (动物品系、年龄、剂量、频率及周期、检测时间及指标等)。

    Doxorubicin hydrochloride 可用于诱导心脏毒性和心力衰竭模型。

    1. 诱导心脏毒性[10]
    致病原理
    短期诱导心脏毒性的机制：促进心肌细胞外重构诱导心力衰竭，还在分子层面上起作用。包括：与铁相互作用，改变细胞内或线粒体内氧化酶的活性，以及与拓扑异构酶结合。
    具体造模方法：
    小鼠：Female C57BL/6j 小鼠 • 20-22 g • 6 周龄
    给药方式：2 mg/kg, 10 mg/kg • 腹腔注射 • 每隔一天注射一次，连续 2 或 3 次
    Note
    第一次注射后 3 天处死小鼠。
    造模成功指标
    分子层面变化：（1）促炎细胞因子（例如 TNF-α 和 IL-6）大量增加，同时抗炎细胞因子 IL-10 减少；（2）心脏组织中诱导型一氧化氮合酶 (iNOS) 过度表达以及血清亚硝酸盐水平升高；硝基酪氨酸的表达显着增加。
    相关产品：/
    拮抗产品：/

    2. 诱导心力衰竭[11]
    致病原理
    诱发心力衰竭的长期机制仍有待仔细阐明。
    具体造模方法：
    大鼠：雄性 Wistar 大鼠 • 180-200 g
    给药方式：2.5 mg/kg • 腹腔注射 • 每周 1 次，共 6 周 • 饲养 4 周后给药
    造模成功指标
    细胞/组织层面：心肌的肌节被破坏，线粒体肿胀和受损， 心肌细胞出现炎症和凋亡（投射电镜结果）；心肌纤维化、左心室胶原 I 和 II 水平下调（免疫组化结果）。
    宏观指标变化：血流动力学参数和超声心动图显示心功能不全，左室功能受损；如 LVIDd、LVIDs 和 LVEDP 升高。
    相关产品：/
    拮抗产品：Captopril (HY-B0368)

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Female MF1 nu/nu mice bearing MDA-G8 breast tumor xenograft (6-week-old)[6]
    Dosage: Doxorubicin (2 mg/kg); Zoledronic acid (100 μg/kg)
    Administration: Intravenous injection; once a week; 6 weeks
    Result: Moderate inhibition of subcutaneous tumor growth in mice that were treated with 2 mg/kg Doxorubicin alone or with 100 μg/kg Zoledronic acid alone compared to the saline control.
    Mice treated with Zoledronic acid and Doxorubicin together had statistically significant smaller mean tumor volumes on day 42 than those treated with Doxorubicin alone.
    Animal Model: Male Sprague-Dawley rats[7]
    Dosage: 1%, 2%, 4%, 5%, 6%, 10%, 20%
    Administration: Intrastriatal injection; Single dose
    Result: In doses of 4, 5, 6, 10 or 20% caused obvious loss of ipsilateral SNc and VTA neuronsz and doses of 1 or 2% failed to produce obvious neuron loss.
    Clinical Trial
    分子量

    579.98

    Formula

    C27H30ClNO11
    CAS 号
    性状

    固体

    颜色

    Orange to red

    中文名称

    盐酸阿霉素；盐酸多柔比星
    结构分类
    初始来源

    Streptomyces peucetius var. Caesius
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    4°C, sealed storage, away from moisture and light

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

    溶解性数据
    细胞实验： 

    H2O 中的溶解度 : 50 mg/mL (86.21 mM; 超声助溶 (<60°C))

    DMSO 中的溶解度 : 25 mg/mL (43.10 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 1.7242 mL 8.6210 mL 17.2420 mL
    5 mM 0.3448 mL 1.7242 mL 3.4484 mL
    查看完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
    储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

    * 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

    • 摩尔计算器

    • 稀释计算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量
    =
    浓度
    ×
    体积
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start)

    C1

    ×
    体积 (start)

    V1

    =
    浓度 (final)

    C2

    ×
    体积 (final)

    V2

    动物实验：

    请根据您的 实验动物和给药方式 选择适当的溶解方案。

    以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
    ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
    以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

    • 方案 一

      请依序添加每种溶剂： 5% DMSO    40% PEG300    5% Tween-80    50% Saline

      Solubility: ≥ 2.75 mg/mL (4.74 mM); 澄清溶液

    • 方案 二

      请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (3.59 mM); 澄清溶液

      此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。

      以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水 定容至 1 mL。

      生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。

    以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比； 如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

    • 方案 一

      请依序添加每种溶剂： Saline

      Solubility: 6 mg/mL (10.35 mM); 澄清溶液; 超声助溶

    动物溶解方案计算器
    请输入动物实验的基本信息：

    给药剂量

    mg/kg

    动物的平均体重

    g

    每只动物的给药体积

    μL

    动物数量

    只
    由于实验过程有损耗，建议您多配一只动物的量
    计算结果
    工作液所需浓度 : mg/mL
    该产品水溶性佳，请具体参考实测 水 / PBS / Saline 中的溶解度数据。
    您所需的储备液浓度超过该产品的实测溶解度，如有需要，请与 MCE 中国技术支持联系。
    纯度 & 产品资料

    纯度: 99.90%

    COA (296 KB) HNMR (287 KB) RP-HPLC (244 KB) LCMS (94 KB)

    产品使用指南 (1538 KB)
    参考文献

    Doxorubicin hydrochloride 相关分类

    完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
    储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

    可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
    DMSO / H2O 1 mM 1.7242 mL 8.6210 mL 17.2420 mL 43.1049 mL
    5 mM 0.3448 mL 1.7242 mL 3.4484 mL 8.6210 mL
    10 mM 0.1724 mL 0.8621 mL 1.7242 mL 4.3105 mL
    15 mM 0.1149 mL 0.5747 mL 1.1495 mL 2.8737 mL
    20 mM 0.0862 mL 0.4310 mL 0.8621 mL 2.1552 mL
    25 mM 0.0690 mL 0.3448 mL 0.6897 mL 1.7242 mL
    30 mM 0.0575 mL 0.2874 mL 0.5747 mL 1.4368 mL
    40 mM 0.0431 mL 0.2155 mL 0.4310 mL 1.0776 mL
    H2O 50 mM 0.0345 mL 0.1724 mL 0.3448 mL 0.8621 mL
    60 mM 0.0287 mL 0.1437 mL 0.2874 mL 0.7184 mL
    80 mM 0.0216 mL 0.1078 mL 0.2155 mL 0.5388 mL

    * 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Doxorubicin25316-40-9Hydroxydaunorubicin ADR盐酸阿霉素盐酸多柔比星TopoisomeraseADC PayloadAMPKAutophagyApoptosisHIVHBVMitophagyAntibioticBacterialFluorescent DyeADC CytotoxinAMP-activated protein kinaseHuman immunodeficiency virusHepatitis B virusMitochondrial AutophagyCardiotoxicityNeurotoxicityfluorescenceHelaCRL-6475fluorescence detectionantibioticstumorapoptosisautophagyInhibitorinhibitorinhibit

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称：

    		  

    * 需求量：

    * 客户姓名：

    		 

    * Email：

    * 电话：

    		 

    * 公司或机构名称：

       留言给我们：

    Bulk Inquiry

    Inquiry Information

    产品名称：
    Doxorubicin hydrochloride
    目录号：
    HY-15142
    需求量：

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

       产品名称：

    		  

    * Lot #：

    * 客户姓名：

    		 

    * Email：

       电话：

    		 

    * 部门：

    * 公司或机构名称：

    		 

       留言给我们：

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.

    嗨！很高兴为您提供帮助！

    尊敬的 MCE 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z